CN1303374A - Substituted indolinones, production thereof and their use as medicaments - Google Patents

Substituted indolinones, production thereof and their use as medicaments Download PDF

Info

Publication number
CN1303374A
CN1303374A CN99806884A CN99806884A CN1303374A CN 1303374 A CN1303374 A CN 1303374A CN 99806884 A CN99806884 A CN 99806884A CN 99806884 A CN99806884 A CN 99806884A CN 1303374 A CN1303374 A CN 1303374A
Authority
CN
China
Prior art keywords
methyl
amino
phenyl
alkyl
methylene radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99806884A
Other languages
Chinese (zh)
Inventor
阿明·赫克尔
雷纳·沃尔特
沃尔夫冈·格雷尔
雅各布斯·C·A·范米尔
诺伯特·里德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim GmbH
Publication of CN1303374A publication Critical patent/CN1303374A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Abstract

The invention relates to substituted indolinones of general formula (I) in which R<1> to R<5> and X are defined as in Claim 1, to the isomers thereof, and to their salts, especially to the physiologically compatible salts thereof, which exhibit valuable pharmacological characteristics, especially an inhibiting effect on different kinases and cyclin/CDK complexes, and on the proliferation of different tumor cells. The invention also relates to medicaments containing these compounds, to their use, and to a method for the production thereof.

Description

The dihydroindole ketone that replaces, its method for making and as the purposes of pharmaceutical composition
The invention relates to down the dihydroindole ketone that is substituted of the novelty of general formula Its isomer and salt, particularly its physiological acceptable salt have valuable character.
The compound of above-mentioned formula I, wherein R 1Being a hydrogen atom or a prodrug base, having valuable pharmacological character, particularly for various kinases, at first is for CDKs (CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and CDK9) and its specific cyclin (A, B1, B2, C, D1, D2, D3, E, F, G1, G2, H, I and K) and the virocyte cyclin (with reference to L.Mengtao, J.Virology 71 (3), 1984-1991 (1997)) mixture inhibited, other compounds of above-mentioned formula I, wherein R 1Be not hydrogen atom or prodrug base, it is the valuable intermediate product of preparation above-claimed cpd.
Therefore, the invention relates to the compound of above-mentioned formula I, wherein R 1Be the compound of a hydrogen atom or a prodrug base, it has valuable pharmacological character, contains the pharmaceutical composition of pharmacologically active chemical compounds, its purposes, and method for making.
In last formula I
X is oxygen or sulphur atom,
R 1Be a hydrogen atom, C 1-4-alkoxy carbonyl, or C 2-4-alkyloyl,
R 2Be a carboxyl, or C 1-4-alkoxyl group-carbonyl, or aminocarboxyl in case of necessity can be by one or two C 1-3-alkoxyl group replaces, and substituting group can be identical or different,
R 3Be a hydrogen atom, or C 1-6-alkyl, it can relate to R 3-C (R 4NR 5Go up by a fluorine, chlorine or bromine atom, hydroxyl, C for 2 of the carbon atom of)=base 1-3-alkoxyl group, C 1-3-alkyl sulphinyl, C 1-3-alkyl sulfinyl, C 1-3-alkyl sulphonyl, phenyl sulfinyl, phenyl sulfinyl, phenyl sulfonyl, amino, C 1-3-alkylamino, two-(C 1-3-alkyl-amino, C 2-5-alkanoylamino, or N-(C 1-3-alkylamino)-C 2-5-alkanoylamino replaces,
R 4Be a hydrogen atom, C 1-6-alkyl, or in case of necessity by C 1-3The C that-alkyl replaces 5-7-cycloalkyl is wherein relating to R 3-C (R 4NR 5The methylene radical of 3 or 4 positions of the carbon atom of)=base in case of necessity can be by C 1-3The imino-that-alkyl replaces replaces,
Phenyl or naphthyl can be by following replacement
One fluorine, chlorine, the bromine or iodine atom,
One methoxyl group is replaced by 1 to 3 fluorine atom in case of necessity,
One C 2-3-alkoxyl group can be in 2 or 3 positions by a C 1-3-alkylamino, two-(C 1-3-alkyl)-amino, or 5 to 7 Yuans cycloalkylidene imino-s replacements, alkyl can replace through a phenyl in addition in abovementioned alkyl amino and dialkyl amido,
Trifluoromethyl, amino, C 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, C 2-5-alkanoylamino, N-(C 1-3-alkyl)-C 2-5-alkanoylamino, C 1-5-alkyl sulfonyl-amino, N-(C 1-3-alkyl)-C 1-5-alkyl sulfonyl-amino, phenyl sulfonyl amino, N-(C 1-3-alkyl)-and phenyl sulfonyl amino, amino-sulfonyl, C 1-3-alkyl amino sulfonyl, or two-(C 1-3-alkyl)-and amino-sulfonyl, alkyl can replace through a phenyl in addition in abovementioned alkyl amino and the dialkyl amido,
One carbonyl, it is through monohydroxy, C 1-3-alkoxyl group, amino, C 1-3-alkylamino, or N-(C 1-5-alkyl)-C 1-3-alkylamino replaces, and moieties can be in addition through a carboxyl, C in the above-mentioned base 1-3-alkoxy carbonyl, or phenyl replacement, or at 2 or 3 position two-(C 1-3-alkyl)-and amino, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of 5 to 7 Yuans ring alkylideneiminos,
One C 1-3-alkyl is through an amino, C 1-7-alkylamino, C 5-7-epoxy group(ing) amino, C 5-7-cycloalkyl-C 1-3-alkylamino, or phenyl-C 1-3-alkylamino replaces, and amino nitrogen-atoms again can be through a C 1-3-alkyl replaces, and wherein hydrogen atom can all or part ofly be substituted by fluorine atom, through C 5-7-cycloalkyl, C 2-4-thiazolinyl, or C 1-4-alkyl replaces,
C in above-mentioned each situation 1-4-alkyl substituent again can be in addition through a cyano group, carboxyl, C 1-3-alkoxy carbonyl, pyridyl, imidazolyl, benzo [1,3] one, two of dioxole (dioxole), or phenyl, or three replacements, wherein phenyl can be through fluorine, chlorine, or bromine atoms, methyl, methoxyl group, trifluoromethyl, cyano group, or nitro replacement, substituting group can be identical or different, or can replace through monohydroxy in 2,3 or 4 positions
One C 1-3-alkyl, it can be through monohydroxy, carboxyl, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of N-phenyl-Piperazine base, through one 5 to 7 Yuans ring alkenylene imino-s, or the replacement of 4 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two C 1-3Alkyl is through a C 5-7-cycloalkyl or phenyl are through a C 1-3-alkyl, C 5-7-cycloalkyl, phenyl, carboxyl, or C 1-4-alkoxyl group-carbonyl, and through the monohydroxy replacement, the methylene radical in abutting connection with nitrogen-atoms in the above-mentioned ring alkylideneimino can replace by a carbonyl again,
One C 1-3-alkyl, it replaces through one 5 to 7 Yuans ring alkylideneiminos, wherein, can condense one in case of necessity by fluorine by two adjacent carbonss in above-mentioned 5 to 7 Yuans ring alkylideneiminos, chlorine or bromine atom or methyl or methoxy one or dibasic phenyl, wherein substituting group can be identical or different, or condense selective ground warp one fluorine, chlorine, bromine, or iodine atom, or methyl, methoxyl group, or the amino De oxazolyl that replaces, imidazolyl, thiazolyl, pyridyl, pyrazinyl, or pyrimidyl
Above-mentioned can be through mono-substituted phenyl through a fluorine, chlorine, or bromine atoms, or methyl, methoxyl group, or nitro replaces,
Be 5 Yuans heteroaryls, contain an imino-, oxygen or sulphur atom or an imino-, oxygen or sulphur atom and one or two nitrogen-atoms, or
Be 6 Yuans heteroaryls, contain one, two, or three nitrogen-atoms, wherein, above-mentioned 5 and 6 Yuans heteroaryls again can be by a chlorine or bromine atom or a methyl substituted, or phenyl ring can condense through the carbon atom of two adjacency at above-mentioned 5 or 6 Yuans heteroaryls, and
R 5Table one hydrogen atom or C 1-3-alkyl.
In addition, the carboxyl that exists in the above-mentioned generalformula, amino, or imino-can be through the in vivo base replacement of cleavable.
Except that above-mentioned alkoxy carbonyl and alkyloyl, in vivo the base of cleavable comprises acyl group, as benzoyl, and pyridine acyl, pentanoyl, or caproyl, allyl group oxygen base carbonyl, C 1-16-alkoxy carbonyl, as pentyloxy carbonyl, hexyloxy carbonyl, octyl group oxygen base carbonyl, nonyl oxygen base carbonyl, decyl oxygen base carbonyl, undecyl oxygen base carbonyl, dodecyl oxygen base carbonyl, or hexadecyl oxygen base carbonyl, phenyl-C 1-6-alkoxy carbonyl is as phenmethyl oxygen base carbonyl, phenyl ethoxy carbonyl, or phenyl propoxycarbonyl, C 1-3-alkyl sulphonyl-C 2-4-alkoxy carbonyl, C 1-3-alkoxy-C 2-4-alkoxy-C 2-4-alkoxy carbonyl, or R cCO-O-(R dCR e)-O-CO-base, wherein
R cBe C 1-8-alkyl, C 5-7-cycloalkyl, phenyl, or phenyl-C 1-3-alkyl,
R eBe a hydrogen atom, C 1-3-alkyl, C 5-7-cycloalkyl, or phenyl, and
R dBe a hydrogen atom, or C 1-3-alkyl, or R cCO-O-(R dCR e)-O-base,
Above-mentioned ester group also can be used as one can be in the base that in vivo is converted into carboxyl.
Yet the preferred compound of formula I is for wherein
X is a Sauerstoffatom,
R 1Be a hydrogen atom,
R 2One aminocarboxyl,
R 3Be a hydrogen atom, or C 1-4-alkyl can relate to R 3-C (R 4NR 52 positions, the one chlorine or bromine atom or phenyl alkylsulfonyl of the carbon atom of)=base replaces,
R 4Be a hydrogen atom, C 1-3-alkyl, or in case of necessity by methyl substituted cyclopentyl, or cyclohexyl, in cyclopentyl and cyclohexyl, relate to R 3-C (R 4NR 5The methylene radical of 3 or 4 positions of the carbon atom of)=base can be substituted by methyl substituted imino-in case of necessity through one,
Be a phenyl, through following replacement:
One fluorine, chlorine, the bromine or iodine atom,
One methoxyl group, selectivity is replaced by 1 to 3 fluorine atom,
One C 2-3-alkoxyl group, it can be in 2 or 3 positions through methylamino, dimethylamino, or the replacement of 5 to 7 Yuans ring alkylideneiminos, the methyl in the above-mentioned amino can be replaced by a benzene again,
Trifluoromethyl, amino, C 2-5-alkanoylamino, N-(C 1-3-alkyl)-C 2-5-alkanoylamino, C 1-5-alkyl sulfonyl-amino, N (C 1-3-alkyl)-C 1-5-alkyl sulfonyl-amino, phenyl sulfonyl amino, N-(C 1-3-alkyl)-phenyl sulfonyl amino, or amino-sulfonyl, the moieties in abovementioned alkyl amino and the dialkyl amido can be replaced by a phenyl,
One carbonyl, it is through monohydroxy, C 1-3-alkoxyl group, amino, C 1-3-alkylamino, or N-(C 1-5-alkyl)-C 1-3-alkylamino replaces, and the moieties in the above-mentioned base can be through a carboxyl, C 1-3-alkoxy carbonyl, or phenyl replacement, or at 2 or 3 position two-(C 1-3-alkyl)-and amino, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of 5 to 7 Yuans ring alkylideneiminos,
One C 1-3-alkyl is through an amino, C 1-7-alkylamino, C 5-7-cycloalkyl amino, C 5-7-cycloalkyl-C 1-3-alkylamino, or phenyl-C 1-3-alkylamino replaces, and amino nitrogen-atoms can be in addition through a C 1-3-alkyl replaces, and wherein hydrogen atom can all or part ofly be substituted by fluorine atom, through C 5-7-cycloalkyl, C 2-4-thiazolinyl, or C 1-4-alkyl replaces,
C in above-mentioned each situation 1-4-alkyl substituent again can be by a cyano group, carboxyl, C 1-3-alkoxy carbonyl, pyridyl, imidazolyl, benzo [1,3] benzodioxoles (dioxole), or the phenyl replacement, wherein phenyl can be through a fluorine, chlorine, or bromine atoms, methyl, methoxyl group, cyano group, trifluoromethyl, or nitro one replacement, or through fluorine, chlorine, or bromine atoms, or methyl, or methoxyl group two or three replacements, substituting group can be identical or different, or can be replaced by monohydroxy in 2,3 or 4 positions
One C 1-3-alkyl, it can be through monohydroxy, carboxyl, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of N-phenyl-Piperazine base, through one 5 to 7 Yuans ring alkenylene imino-s, or the replacement of 4 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two C 1-3-alkyl is through a cyclohexyl or phenyl, through a C 1-3-alkyl, cyclohexyl, phenyl, carboxyl, or C 1-4-alkoxyl group-carbonyl, and through the monohydroxy replacement, the methylene radical in abutting connection with nitrogen-atoms in the above-mentioned ring alkylideneimino can replace by a carbonyl,
One C 1-3-alkyl, it replaces through one 5 to 7 Yuans ring alkylideneiminos, encircle alkylideneimino above-mentioned 5-7 person and condense one in case of necessity by fluorine by two adjacent carbon atoms, chlorine or bromine atom or methyl or methoxy one or dibasic phenyl, (wherein substituting group can be identical or different), or the piperazinyl that is replaced by amino in case of necessity, or thiazolyl
Above-mentioned can be through monobasic phenyl through a fluorine, chlorine, or bromine atoms, or methyl, methoxyl group, or nitro replaces,
Be a pyridyl, selectivity is through a chlorine or bromine atom or a methyl substituted,
Be that a selectivity replaces De oxazolyl ， isoxazolyl through monomethyl, imidazolyl, or thiazolyl, it can condense a phenyl ring through the carbon atom of two adjacency, and
R 5Be a hydrogen atom or C 1-3-alkyl.
Particularly generalformula, wherein R 1To R 3And R 5As above-mentioned definition, and
R 4Be a hydrogen atom, C 1-6-alkyl, or optionally through C 1-3The C that-alkyl replaces 5-7-cycloalkyl wherein relates to R 3-C (R 4NR 5The methylene radical of 3 or 4 positions of the carbon atom of)=base can be through one optionally through a C 1-3The imido grpup that-alkyl replaces substitutes,
One phenyl or naphthyl, can be through following replacement:
One fluorine, chlorine, bromine or iodine atom, C 1-3-alkoxyl group, amino, C 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, C 2-5-sulfuryl amino, N-(C 1-3-alkylamino)-C 2-5-alkanoylamino, C 1-5-alkyl sulfonyl-amino, N-(C 1-3-alkyl)-C 1-5-alkyl sulfonyl-amino, phenyl sulfonyl amino, or N-(C 1-3-alkyl)-phenyl sulfonyl amino, or C 1-3-alkyl, it again can be through a C 1-5-alkylamino, two-(C 1-5-alkyl)-and amino, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, piperazinyl, N-(C 1-3-alkyl)-and piperazinyl, N-phenyl-Piperazine base, C 5-7-ring alkylideneimino, or C 4-7-ring alkylideneimino replaces wherein above-mentioned C 5-7-ring alkylideneimino can be through one or two C 1-3-alkyl is through a C 5-7-cycloalkyl or phenyl are through a C 1-3-alkyl, C 5-7-cycloalkyl, phenyl, carboxyl, or C 1-4-alkoxyl group-carbonyl, and through the monohydroxy replacement,
Its isomer and salt.
Particularly preferred generalformula is R wherein 1To R 5As above-mentioned definition and R 25 position persons,
Special compound, wherein
X is a Sauerstoffatom,
R 1Be a hydrogen atom,
R 2In 5 positions, be an aminocarboxyl,
R 3Be a hydrogen atom, or C 1-4-alkyl can replace through a chlorine or bromine atom or phenyl alkylsulfonyl at its end,
R 4Be a hydrogen atom, C 1-3-alkyl, or in case of necessity by methyl substituted cyclopentyl, or cyclohexyl, in cyclohexyl, relate to R 3-C (R 4NR 5The methylene radical of 4 positions of the carbon atom of)=base can substitute through an imino-, and imino-optionally replaces through monomethyl,
One phenyl is through following replacement
One fluorine, chlorine, the bromine or iodine atom,
Monomethyl or ethyl can be through C under each situation 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, N-phenyl-Piperazine base, 5 to 6 Yuans ring alkenylene imino-s, or the replacement of 5 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two methyl, through a cyclohexyl or phenyl, through monomethyl, cyclohexyl, or phenyl, and through the monohydroxy replacement, or
Monomethyl or ethyl, it can replace through the phenyl that one 5 to 7 Yuans ring alkylideneiminos replace, and the carbon atom through two adjacency condenses a phenyl ring on above-mentioned ring alkylideneimino in addition,
Monomethyl or ethyl, through an amino, methylamino, or ethylamino replaces, it also can be replaced by a phenmethyl or styroyl in addition at the nitrogen-atoms of amino, and the phenyl in the wherein above-mentioned base can be by fluorine, chlorine, or bromine atoms, or through monomethyl, methoxyl group, cyano group, trifluoromethyl, or the replacement of nitro list, or through fluorine, chlorine, or bromine atoms, or through methyl, or methoxyl group two or three replacements, each substituting group can be identical or different
Above-mentioned can be through mono-substituted phenyl in addition through a fluorine, chlorine, or bromine atoms, or monomethyl, methoxyl group, or nitro replaces, and
R 5Be a hydrogen atom or C 1-4-alkyl,
Its isomer and salt thereof.
Best generalformula is, wherein
X is a Sauerstoffatom,
R 1Be a hydrogen atom,
R 2In 5 positions are aminocarboxyls,
R 3Be a hydrogen atom or C 1-4-alkyl,
R 4Be a phenyl, it can be through following replacement
One fluorine, chlorine, the bromine or iodine atom,
Monomethyl or ethyl, it can be through a C in each situation 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, N-phenyl-Piperazine base, 5 to 6 Yuans ring alkenylene imino-s, or the replacement of 5 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two methyl, through a cyclohexyl or phenyl, through monomethyl, cyclohexyl, or phenyl, and through the monohydroxy replacement, or
Monomethyl or ethyl, it can replace through a phenyl that is replaced by 5 to 7 Yuans ring alkylideneiminos in 4 positions, and the carbon atom through two adjacency can condense a phenyl ring on above-mentioned ring alkylideneimino in addition,
Monomethyl or ethyl, it is through an amino, methylamino, or ethylamino replaces, or replaced by a phenmethyl in addition at each amino nitrogen-atoms, and wherein phenyl can be through a fluorine, chlorine, or bromine atoms, or through monomethyl, methoxyl group, cyano group, trifluoromethyl, or the replacement of nitro list, replace through methyl or methoxy two, or replace through methyl or methoxy three, each substituting group can be identical or different
Above-mentioned can be through mono-substituted phenyl through a fluorine, chlorine, or bromine atoms, or monomethyl, methoxyl group, or nitro replaces, and
R 5Be a hydrogen atom or C 1-4-alkyl,
Its isomer and salt.
Followingly address special good examples for compounds:
(a) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(b) 3-Z-[1-(4-bromo-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(c) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-butyl-methylene radical]-5-amido-2-dihydroindole ketone,
(b) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(e) 3-Z-(1-phenyl amino-methylene radical)-5-amido-2-dihydroindole ketone,
(f) 3-Z-[1-(4-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(g) 3-Z-[1-(4-(N-(4-chlorophenylmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(h) 3-Z-[1-(4-N-phenmethyl-N-ethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(i) 3-Z-[1-(4-N-phenmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(j) 3-Z-[1-(4-N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-methylene radical]-5-amido-2-dihydroindole ketone,
(k) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenmethyl)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(1) 3-Z-[1-(4-piperidino methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone, and
(m) 3-Z-[1-(4-methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
And isomer and salt thereof.
According to the present invention, compounds can for example obtain by known method in the following document:
A. descend the amine reaction of the compound and the logical formula III of general formula: In the formula II
X and R 3As above-mentioned definition,
R 2' have an above-mentioned R 2Meaning,
R 6Be the protecting group of the nitrogen-atoms of a hydrogen atom or a lactam group, wherein, R 2' or R 6One of base also can be a key that is bonded in a solid phase that optionally forms through a spacer, another R 2' or R 6Base as above-mentioned definition, and
Z 1The table halogen atom, hydroxyl, alkoxyl group, or aralkoxy, a for example chlorine or bromine atom, an or methoxyl group, oxyethyl group, or phenmethyl oxygen base,
Figure A9980688400182
In the formula III
R 4And R 5As above-mentioned definition,
If need, then used protecting group or the solid phase of the nitrogen-atoms of cracking lactam group.
As the example of the suitable protecting group of the nitrogen-atoms of lactam group, as ethanoyl, benzoyl, ethoxy carbonyl, tert-butoxycarbonyl, or phenmethyl oxygen base carbonyl.
As solid phase can be resin for example, as 4-(2 ', 4 '-the Dimethoxyphenyl amino methyl)-phenoxy resin, wherein preferred combination is to carry out through amino, or right-phenmethyl oxygen base benzylated polyol resin, wherein preferred combination be through middle member as 2,5-dimethoxy-4 '-hydroxyl-phenmethyl derivative carries out.
Reaction is suitable for carrying out in solvent, as dimethyl formamide, and toluene; acetonitrile; tetrahydrofuran (THF), methyl-sulphoxide, methylene dichloride; or in its mixture; optionally inactive alkali such as triethylamine are being arranged, N-ethyl-diisopropylamine, or sodium bicarbonate exists down; temperature between 20 to 175 ℃ is carried out, and used any protecting group can be carried out cracking when changeing acyl amination.
If the Z in the general formula II compound 1Be halogen atom, then reaction preferably in the presence of inactive alkali, is carried out under the temperature between 20 to 120 ℃.
If the Z of general formula II compound 1Be hydroxyl, alkoxyl group, or aralkoxy, then reaction is preferably carried out under the temperature between 20 to 200 ℃.
If need, the cracking of used any protecting group is suitable for carrying out in water or alcoholic solvent, for example in methanol; ethanol/water, isopropanol, tetrahydrofuran (THF)/water diox/water, dimethyl formamide/water, methyl alcohol; or in the ethanol, in that alkali metal base is arranged, as lithium hydroxide; sodium hydroxide, or there is down the temperature between in 0 to 100 ℃ in potassium hydroxide; preferably hydrolysis under the temperature between 10 to 50 ℃
Or more favourable be with organic bases, as ammonia, methylamine, butylamine, dimethylamine, or piperidines, in solvent, as methyl alcohol, ethanol, dimethyl formamide, and composition thereof in, or in used excess amine, under the temperature between 0 to 100 ℃, preferably under the temperature between 10 to 50 ℃, change acyl amination.
Used any solid phase preferably with trifluoracetic acid and water under 0 to 35 ℃ temperature, preferably cracking at ambient temperature.
B. be R in the preparation formula I 2Be the compound of one of above-mentioned aminocarboxyl:
To descend the amine of general formula IV compound or its response derivative and general formula (V) to carry out acyl amination
Figure A9980688400191
R in the formula IV 1And R 3As above-mentioned definition,
H-(R 7NR 8) the middle R of (V) formula (V) 7And R 8Can be identical or different, be hydrogen atom or C 1-3-alkyl.
Acyl amination preferably carries out in solvent, as methylene dichloride, and diethyl ether, tetrahydrofuran (THF), toluene ， diox, acetonitrile, methyl-sulphoxide, or in the dimethyl formamide, optionally in the presence of mineral alkali or uncle's organic bases, preferably carry out between the boiling temperature of solvent for use at 20 ℃.Acyl amination is that relative acid is being arranged, preferably in the presence of dewatering agent, for example at isobutyl chlorocarbonate, tetraethyl orthocarbonate, original trimethyl acetate, 2, the 2-Propanal dimethyl acetal, tetramethoxy-silicane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, five phosphorus oxide, N, N ＇-dicyclohexyl carbodiimide, N, N ＇-dicyclohexyl carbodiimide/N-hydroxy-succinamide, N, N ＇-dicyclohexyl carbodiimide/1-hydroxyl-benzotriazole, Tetrafluoroboric acid 2-(1H-benzotriazole-1-yl)-1,1,3, the 3-tetramethyl-
Figure A9980688400201
(uronium), Tetrafluoroboric acid 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl-
Figure A9980688400202
/ 1-hydroxyl-benzotriazole, N, N ＇-carbonyl dimidazoles; or in triphenylphosphine/tetracol phenixin, and randomly add alkali, as pyridine; 4-dimethylamino-pyridine; N-methylmorpholine, or triethylamine, temperature between 0 to 150 ℃ suits; preferably under the temperature between O to 100 ℃, carry out; acidylate is and corresponding reactive compounds, as its acid anhydride, ester; the imidazoles thing; or halogenide, optionally in that uncle's organic bases is arranged, as triethylamine; the N-ethyl diisopropyl amine; or the N-methylmorpholine existence down, and the temperature between 0 to 150 ℃ is preferably carried out under the temperature between 50 to 100 ℃.
Prepare the generalformula that contains an alkoxy carbonyl of the present invention, it can be converted into corresponding carboxylic compound by hydrolysis, or
Preparation contains the generalformula of amino or alkylamino, and it can be converted into corresponding alkylamino or dialkylamino compound by alkylation or reductive alkylation, or
Make the general formula compound that contains amino or alkylamino, it can be converted into corresponding acyl compounds by acidylate, or
Make the generalformula that contains a carboxyl, it can be converted into corresponding ester or aminocarboxyl compound by esterification or amidated, or
Make the general formula compound that contains a nitro, it can be converted into corresponding aminocompound by reduction.
Hydrolysis is then preferably carried out in aqueous solvent, for example in water, and isopropanol, tetrahydrofuran (THF)/water in Huo diox/water, is having acid, as trifluoracetic acid, hydrochloric acid, or sulfuric acid exists down, or at alkali metal base, as lithium hydroxide, sodium hydroxide, or potassium hydroxide exists down, temperature between 0 to 100 ℃ is preferably carried out under the temperature between 10 to 50 ℃.
Reductive alkylation preferably carries out in the solvent that is fit to, as methyl alcohol, and methanol, methanol/ammonia, ethanol/ether, tetrahydrofuran (THF) ， diox, or in the dimethyl formamide, selectivity adds acid, and example hydrochloric acid is having in the presence of the catalytic activation hydrogen, for example Raney nickel is being arranged, platinum, or the hydrogen under palladium/charcoal existence, or in that metal hydride is arranged, as sodium borohydride, lithium borohydride, or the lithium aluminum hydride existence down, and the temperature between in 0 to 100 ℃ is carried out under the preferable temperature between 20 to 80 ℃.
Alkylation is with alkylating agent, as alkylogen or dialkylsulfates, and as methyl-iodide, the dimethyl sulphide acid esters, or propyl bromide, preferably in solvent, as methyl alcohol, ethanol, methylene dichloride, tetrahydrofuran (THF), toluene ， diox, methyl-sulphoxide, or in the dimethyl formamide, randomly in that mineral alkali or uncle's organic bases are arranged, as triethylamine, N-ethyl-diisopropylamine, or the dimethyl aminopyridine existence is down, preferably carries out between the boiling temperature of solvent for use at 20 ℃.
Acidylate is preferably in solvent, as methylene dichloride, and ether, tetrahydrofuran (THF), toluene, diox, acetonitrile, methyl-sulphoxide, or in the dimethyl formamide, randomly having in the presence of mineral alkali or the uncle's organic bases, preferably carry out between the boiling temperature of solvent for use at 20 ℃.Acidylate is and relative acid preferably to have in the presence of the dewatering agent, for example at isobutyl chlorocarbonate; tetraethyl orthocarbonate, original trimethyl acetate, 2; 2-dimethoxy Ethylene Oxide; tetramethoxy-silicane, thionyl chloride, trimethylchlorosilane; phosphorus trichloride; five phosphorus oxide, N, N ＇-dicyclohexyl carbodiimide; N; N ＇-dicyclohexyl carbodiimide/N-hydroxy-succinamide, N, N ＇-dicyclohexyl carbodiimide/1-hydroxyl-benzotriazole; Tetrafluoroboric acid 2-(1H-benzotriazole-1-yl)-1; 1,3, the 3-tetramethyl- (uronium), Tetrafluoroboric acid 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl-
Figure A9980688400212
/ 1-hydroxyl-benzotriazole, N, N ＇-carbonyl dimidazoles; or in triphenylphosphine/tetracol phenixin, selectivity adds alkali, as pyridine; 4-dimethylamino-pyridine; N-methylmorpholine, or triethylamine are suitable for the temperature between 0 to 150 ℃; preferably under the temperature between 0 to 100 ℃, carry out; acidylate is the reactive compounds with correspondence, as its acid anhydride, ester; the imidazoles thing; or halogenide, optionally at uncle's organic bases, as triethylamine; the N-ethyl diisopropyl amine; or the N-methylmorpholine existence down, and the temperature between in 0 to 150 ℃ is preferably carried out under the temperature between 50 to 100 ℃.
Esterification or amidated are suitable for carrying out with corresponding alcohol or amine reaction by the reactive carboxylic acid derivatives of correspondence, as mentioned above.
The reduction of nitro is preferably undertaken by hydrogenolysis, for example uses hydrogen in the presence of catalyzer such as palladium/charcoal or Raney nickel, at solvent such as methyl alcohol, ethanol, vinyl acetic monomer, dimethyl formamide is in dimethyl formamide/acetone or the Glacial acetic acid, optionally add acid, example hydrochloric acid or Glacial acetic acid, the temperature between 0 to 50 ℃, but preferably in room temperature, in hydrogen pressure 1 to 7 crust, but preferably under 3 to 5 crust, carry out.
In above-mentioned reaction, the reactive base of any existence, as carboxyl, amino, alkylamino, or imino-can during reaction can cracked protecting group protections again after reaction with known.
For example, the protecting group of carboxyl can be a TMS, methyl, ethyl, the tertiary butyl, phenmethyl, or THP trtrahydropyranyl;
Amino, alkylamino, or the protecting group of imino-can be ethanoyl, trifluoroacetyl group, benzoyl; the oxyethyl group carbon back, tert.-butoxy carbon back, phenmethyl oxygen base carbonyl, phenmethyl; mehtoxybenzyl, or 2,4-dimethoxy phenmethyl, amino protecting group can also be a phthaloyl.
The selective splitting of used any protecting group is for example by the hydrolysis in aqueous solvent, for example in water; isopropanol, tetrahydrofuran (THF)/water is in Huo diox/water; in that acid is arranged, as trifluoracetic acid, hydrochloric acid; or the sulfuric acid existence down, or alkali metal base is being arranged, as lithium hydroxide; sodium hydroxide; or the potassium hydroxide existence down, and the temperature between 0 to 100 ℃ is preferably carried out under the temperature between 10 to 50 ℃.
Yet, phenmethyl, mehtoxybenzyl, or phenmethyl oxygen base carbonyl can be for example with the hydrogenolysis cracking, for example with hydrogen in the presence of catalyzer such as palladium/charcoal, in The suitable solvent, methyl alcohol for example, ethanol, vinyl acetic monomer, dimethyl formamide in dimethyl formamide/acetone or the Glacial acetic acid, optionally adds acid, example hydrochloric acid or Glacial acetic acid, the temperature between 0 to 50 ℃, but preferably in room temperature, at hydrogen pressure 1 to 7 crust, but preferably under 3 to 5 crust, carry out.
Mehtoxybenzyl also can be in the presence of oxygenant such as cerous nitrate (IV) ammonium, in solvent such as methylene dichloride, and acetonitrile, or in the acetonitrile/water, the temperature between 0 to 50 ℃, preferably cracking at room temperature.
Yet, 2, the cracking of 4-dimethoxy phenmethyl is preferably carried out in having in the presence of the methyl-phenoxide in trifluoracetic acid.
The tertiary butyl or tertiary butyl oxygen carbonyl preferably use acid as trifluoracetic acid or salt acid treatment, optionally use solvent such as methylene dichloride, diox, and vinyl acetic monomer, or ether carries out cracking.
Phthaloyl is preferably at hydrazine or primary amine such as methylamine, ethamine, or n-Butyl Amine 99 exists down, at solvent such as methyl alcohol, and ethanol, Virahol, toluene in the Huo diox, is carried out cracking under the temperature between 20 to 50 ℃.
In addition, the formula I that is obtained can resolve to its enantiomorph and/or diastereomer to chipal compounds.
Therefore, for example, the generalformula that is racemic modification that is obtained can separate with currently known methods (with reference to Allinger N.L.and Eliel E.L. " Topics in Stereochemistry ", Vol.6, WileyInterscience, 1971) become its optically active enantiomorph (antipodes), generalformula with at least 2 unsymmetrical carbons can use currently known methods, based on for example chromatography and/or the fractional crystallization of its physical-chemical difference, resolve to its diastereomer, if obtain the racemic form of these compounds, can be as the above-mentioned enantiomorph that resolves to.
The purifying of enantiomorph preferably can be separated by the post based on the chirality phase, or separate by recrystallize in the photolytic activity solvent, or form the optical active substance of salt or derivative such as ester or acid amides with a kind of and racemic compound, particularly its acid and activated derivatives thereof or alcohol reaction, and separate the salt obtained or the non-enantiomer mixture of derivative, for example based on the otherness of its solubleness, free enantiomorph can be by the appropriate formulation effect by discharging in pure diastereoisomeric salt or the derivative.The general photolytic activity acid of using is for example tartrate or dibenzoyl tartaric acid, two-neighbour-tolyl tartrate, oxysuccinic acid, phenylglycollic acid, camphorsulfonic acid, L-glutamic acid, aspartic acid, N-ethanoyl-aspartic acid, or the D of quininic acid and L shaped formula.Photolytic activity alcohol can be (+) or (-)  alcohol for example, and the photolytic activity acyl group can be (+) or (-)  base oxygen base carbonyl for example in the acid amides.
In addition, formula I compound can be converted into its salt with inorganic or organic acid, and is particularly medicinal, physiologically acceptable salt.The acid that can be used for this purpose comprises for example hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, fumaric acid, succsinic acid, lactic acid, citric acid, tartrate, toxilic acid, or methylsulfonic acid.
In addition,,, can be converted into its salt with inorganic or organic bases if need if formula I compound contains a carboxyl, particularly medicinal, its physiologically acceptable salt.Suitable alkali for this purpose comprises for example sodium hydroxide, potassium hydroxide, hexahydroaniline, thanomin, diethanolamine, and trolamine.
As the formula I of initial substance to the compound of V partly is by known in the document, can or be described in that method makes among the following embodiment by literature method.
As above-mentioned, R in the formula I 1The compounds that is a hydrogen atom or a prodrug base has valuable pharmacological character, particularly for various kinases and cyclin (cycline)/CDK mixture, hyperplasia for the human tumor cell who cultivates has restraining effect, and when oral using, inhibited for the tumor growth of the nude mice (nude mice) that infects the human tumor cell.
For example, the compound shown in the table 1 is pressed test organisms character.Test the restraining effect of 1 cyclin/CDK enzyme, activity in vitro
Use High Five TMInsect cell (BTI-TN-581-4), it has infected the recombinant baculovirus (baculovius) that has height to tire, to produce active human cell's cyclin/CDK holoenzyme (holoenzymes).Contain the baculovirus vector of two kinds of promoters (polyhedron enhanser promoter, P10 enhanser promoter) by use, make to have corresponding His 6The GST-target cell cyclin of the CDK subunit of-mark (for example CDK 4 or CDK6) (for example cyclin D1 or cyclin D3) is expressed in same cell.Active holoenzyme is to separate with the affinity chromatography on the glutathione agarose gel.The pRB of the GST-mark of recombinant chou (amino acid 379-928) produces in intestinal bacteria (E.Coli), and on the glutathione agarose gel with the affinity purification by chromatography.
Kinases is analyzed used matrix and is decided by specific kinases.Use Histone H1 (Sigma) as cyclin E/CDK 2, cyclin A/CDK 2, cell periodic protein B/CDK 1, and the matrix of v-cyclin/CDK 6.The pRB (amino 379-928) that uses the GST-mark is as cyclin D1/CDK4, cyclin D3/CDK4, cyclin D1/CDK6, and the matrix of cyclin D3/CDK6.
Infection has the lysate of recombinant baculovirus insect cell or recombinant chou kinases (being obtained by the lysate purifying) to cultivate 45 minutes at 30 ℃ in 1%DMSO (methyl-sulphoxide) solution with various concentration inhibitor in the presence of suitable matrix with radiolabeled ATP.Having radioactive stroma protein precipitates on Whatman P81 filter in many wells of the PVDF of waterproof titer plate (Millipore) or with 0.5% phosphoric acid solution with 5%TCA (Tricholroacetic Acid).After adding scintillating liquid, in Wallac 1450Microbeta Liquid Scimillation Counter, measure its radioactivity.Carrying out secondary for each concentration matrix measures; Calculate the inhibition IC of its enzyme 50Value.The outgrowth inhibition of human tumor cell that test 2 is cultivated
The cell (deriving from ATCC) of smooth muscle tumour cell SK-UT-IB is incubated at minimum essential medium, it contains non-essential amino acid (Gibco), is supplemented with Sodium.alpha.-ketopropionate (1 mmole), glutamine (2 mmole), and 10% foetal calf serum (Gibco), collect at logarithmic phase.Then the SK-UT-1B cell is added Cytostar In the multiple-well plate (Amersham), 4000 cells of every well density are cultivated in cultivating container and are spent the night.The compound of various concentration (is dissolved among the DMSO; Ultimate density:＜1%) add in the cell.After cultivating 48 hours, will 14C-thymidine (Aimersham) adds in each well, continues to cultivate 24 hours.To in the presence of inhibitor, mixing in the tumour cell 14The interim cell number of C-thymidine amount and S is measured in Wallace 1450 Microbeta Liquid Scintillation Counter.Calculating the inhibition hyperplasia (suppresses to add 14The C-thymidine) IC 50Value is proofreaied and correct background radiation.All are measured and all carry out secondary.Test 3 pairs of in vivo effects that have the nude mice of tumour
10 6Individual cell (SK-UT-1B), or non-small cell lung tumor NCI-H460 (deriving from ATCC), 0.1 milliliter of volume is gone into male and/or female nude mice (NUMRI nu/nu through subcutaneous injection; The 25-35 gram; N=10-20); Perhaps, small segment SK-UT-1B or NCI-H460 cell mass are implanted subcutaneously.Inject or implantation one to three week of back every day in a kind of 2 to 4 week of kinase inhibitor of oral administration (through esophagus).The size of tumour uses measure digital one week of slide gauge three times.Kinase inhibitor is measured for the effect of tumor growth and the inhibition percentage with the control group comparison of placebo treatment.
Be listed in the result who in vitro tests in 2 to be obtained in the following table:
Compound (embodiment number) The outgrowth inhibition of SKUT-1B IC 50[:M]
1(11) 0.032
1(8) 0.060
1(26) 0.036
1(3) 0.040
1(1) 0.100
1(96) 0.005
1(91) 0.010
1(95) 0.008
1(51) 0.013
1(105) 0.019
1(110) 0.020
1(117) 0.020
1(71) 0.030
Based on its biological property, the compounds of formula I, its isomer, and physiological acceptable salt is applicable to that treatment is the disease of feature with excessive or abnormal cells hyperplasia.
These diseases comprise (but not exclusively): virus infection (as HIV and card ripple agent (Kaposi) sarcoma): inflammation and autoimmune disorders (for example colitis, sacroiliitis, Alzheimer's disease, glomerulonephritis, and wound healing); Bacterium, fungi, and/or parasitic infection; Leukemia, lymphoma and solid tumor; Tetter (for example psoriasis); The skeleton disease; Cardiovascular disorder (for example restenosis and hypertrophy).They also can be used for protecting proliferative cell (for example hair, intestinal cells, blood and my late grandfather (progenitor) cell) to prevent that because of radiation, UV handles and/or the caused dna damage of the static processing of cell.
Compounds can be used for short-term or the above-mentioned disease of long-term treatment, optionally is used in combination with other " prior art " compounds (as other cell arrestants).
Reaching the required dosage of this effect is 0.1 to 30 milligram/kilogram through intravenously suitably, is preferably 0.3 to 10 milligram/kilogram, and oral administration is 0.1 to 100 milligram/kilogram, is preferably 0.3 to 30 milligram/kilogram, uses 1 to 4 time every day in each situation.For this reason, the prepared formula I compound according to the present invention is optionally with other active substances, can with one or more inertia universal support and/or thinner, W-Gum for example, lactose, glucose, Microcrystalline Cellulose, Magnesium Stearate, Polyvinylpyrolidone (PVP), citric acid, tartrate, water, water/ethanol, water/glycerine, water/Sorbitol Powder, water/polyoxyethylene glycol, propylene glycol, the hexadecyl stearyl alcohol, carboxy methyl cellulose, or fatty substance, as tristearin, or its mixture that is fit to allotment, to produce general Galenic formula, as common or coated tablet, capsule, powder, suspension, or suppository.
The following example is in order to illustrate the present invention:
Embodiment I 1-ethanoyl-2-dihydroindole ketone-5-carboxylate methyl ester
10.5 gram 2-dihydroindole ketone-5-carboxylate methyl ester (similar in appearance to Ogawa, people such as Hidenori, Chem-Pharm.Bull 36, the preparation of 2253-2258 (1988)) in 30 milliliters of acetic anhydride, stirred 4 hours at 140 ℃.The throw out suction filtration is poured in the frozen water in mixture cooling then into.Product is washed once with water again, is dissolved into then in the methylene dichloride, and with dried over sodium sulfate, and evaporation concentration.Output: 11 gram (theoretical value 86%) R fValue: 0.63 (silica gel, methylene chloride=50: 1)
Embodiment II 1-ethanoyl-3-(1-oxyethyl group-1-butyl-methylene radical)-2-dihydroindole ketone-5-carboxylate methyl ester
11 gram 1-ethanoyl-2-dihydroindole ketone-5-carboxylate methyl esters stirred 2 hours at 100 ℃ in 110 milliliters of acetic anhydride and 30 milliliters of orthovaleric acid triethyls.Concentrate with rotary evaporation then, resistates is washed with ether, suction filtration.Output: 11.5 gram (theoretical value 67%) R fValue: 0.55 (silica gel, methylene dichloride/sherwood oil/vinyl acetic monomer=4: 5: 1)
Prepare following compounds similar in appearance to the example II:
(1) 1-ethanoyl-3-(1-oxyethyl group-methylene radical)-2-dihydroindole ketone-5-carboxylate methyl ester
By 1-ethanoyl-2-dihydroindole ketone-5-carboxylate methyl ester and trimethyl orthoformate preparation
(2) 1-ethanoyl-3-(1-oxyethyl group-1-methyl-methylene radical)-2-dihydroindole ketone-5-carboxylate methyl ester
By 1-ethanoyl-2-dihydroindole ketone-5-carboxylate methyl ester and original trimethyl acetate preparation
(3) 1-ethanoyl-3-(1-oxyethyl group-1-ethyl-methylene radical)-2-dihydroindole ketone-5-carboxylate methyl ester
By 1-ethanoyl-2-dihydroindole ketone-5-carboxylate methyl ester and triethyl orthopropionate preparation
The embodiment III
28.0 gram Rink resin (by the mbha resin of Novobiochem manufacturing) expands in 330 milliliters of dimethyl formamides.Add the solution of 330 milliliter of 30% piperidines in dimethyl formamide then, mixture shakes 7 minutes with cracking 9H-fluorenes-9-base-methoxycarbonyl.Resin with the dimethyl formamide washing several times then.At last, add 7.3 grams, 10.5 gram 2-dihydroindole ketone-5-carboxylic acids are (similar in appearance to Ogawa, the preparation of Hidenori et al.Chem.Pharm.Bull 36.2253-2258 (1988)), 5.6 gram hydroxybenzotriazoles, 13.3 gram Tetrafluoroboric acid O-(benzotriazole-1-yl)-N, N, N ＇ N ＇-tetramethyl-
Figure A9980688400271
, and the solution of 5.7 milliliters of N-ethyl-diisopropylamines in 300 milliliters of dimethyl formamides, mixture shook 1 hour.Solution suction filtration, resin be with 300 milliliters of dimethyl formamides washing 5 times, with 300 milliliters of washed with dichloromethane 3 times.Nitrogen blows resin to be dried.
Output: the resin of 20 gram loads
The embodiment IV
0.4 load resin and 2.5 milliliters of acetic anhydride prepared in the gram embodiment III stirred 1 hour at 90 ℃.Add 2.5 milliliters of original acid methyl esters then, mixture shook 3 hours at 110 ℃ again.Resin suction filtration then, and with dimethyl formamide, methyl alcohol is at last with washed with dichloromethane.
Output: 0.6 gram wet resin
Prepare following load resin similar in appearance to the embodiment IV:
(1) Supreme Being resin of 3-Z-(1-oxyethyl group-methylene radical)-5-amido-2-dihydroindole ketone is arranged is by the product of embodiment I and triethyl orthoformate reaction and make
(2) resin that has 3-Z-(1-methoxyl group-1-methyl-methylene radical)-5-amido-2-dihydroindole ketone is by the product and the trimethyl orthoacetate reaction of embodiment I and make
(3) resin that has 3-Z-(1-methoxyl group-1-ethyl-methylene radical)-5-amido-2-dihydroindole ketone is by the product and the reaction of former propionic acid trimethyl of embodiment I and make
(4) resin that has 3-Z-(1-methoxyl group-1-propyl group-methylene radical)-5-amido-2-dihydroindole ketone is by the product and the reaction of former butyric acid trimethyl of embodiment I and make
(5) resin that has 3-Z-(1-methoxyl group-1-vinyl-methylene radical)-5-amido-2-dihydroindole ketone is the product and 3,3 by the embodiment I, and 3-triethoxy third-1-alkene reaction makes
(6) resin that has 3-Z-(1-methoxyl group-1-(3-bromo-propyl group)-methylene radical)-5-amido-2-dihydroindole ketone is made by the product and the former butyric acid trimethyl reaction of 4-bromo-of embodiment I
(7) resin that has 3-Z-(1-methoxyl group-1-(2-phenyl sulfonyl-ethyl)-methylene radical)-5-amido-2-dihydroindole ketone is made by product and 3-phenyl sulfonyl-triethyl orthopropionate reaction of example I
Embodiment V 4-(N-ethyl-amino methyl)-oil of mirbane
6 gram 4-oil of mirbane methyl bromines are dissolved in 25 milliliters of ethanol, mix with 25 milliliter of 10% alcoholic acid ethylamine solution, reflux 2 hours.Solution concentrates with rotary evaporation then, and resistates is dissolved in the methylene dichloride, washs with diluted sodium hydroxide solution.Evaporation concentration organic phase then.
Output: 2.3 grams (theoretical value 46%)
R fValue: 0.20 (silica gel, methylene chloride=9: 1)
Prepare following compounds similar in appearance to the embodiment V:
4-[N-(4-chloro-phenyl--methyl)-amino methyl]-oil of mirbane
4-(N-cyclohexyl-amino methyl)-oil of mirbane
4-(N-sec.-propyl-amino methyl)-oil of mirbane
4-(N-butyl-amino methyl)-oil of mirbane
4-(N-methoxycarbonyl methyl-amino methyl)-oil of mirbane
4-(N-phenmethyl-amino methyl)-oil of mirbane
4-(pyrrolidyl-methyl)-oil of mirbane
4-(morpholinyl-methyl)-oil of mirbane
4-(piperidyl-methyl)-oil of mirbane
4-(hexamethyleneimino-methyl)-oil of mirbane
4-(4-hydroxy-piperdine base-methyl)-oil of mirbane
4-(4-methyl-piperidyl-methyl)-oil of mirbane
4-(4-ethyl-piperidyl-methyl)-oil of mirbane
4-(4-sec.-propyl-piperidyl-methyl)-oil of mirbane
4-(4-phenyl-piperidyl-methyl)-oil of mirbane
4-(4-phenmethyl-piperidyl-methyl)-oil of mirbane
4-(4-ethoxy carbonyl-piperidyl-methyl)-oil of mirbane
4-(dimethylamino-methyl)-oil of mirbane
4-(two n-propylamine base-methyl)-oil of mirbane
4-(4-tert-butoxycarbonyl-piperazinyl-methyl)-oil of mirbane
3-(dimethylamino-methyl)-oil of mirbane
4-(2-diethylamino-ethyl)-oil of mirbane
4-(2-morpholinyl-ethyl)-oil of mirbane
4-(2-pyrrolidyl-ethyl)-oil of mirbane
4-(2-piperidyl-ethyl)-oil of mirbane
4-(N-ethyl-N-phenmethyl-amino methyl)-oil of mirbane
4-(N-n-propyl-N-phenmethyl-amino methyl)-oil of mirbane
4-(N-methyl-N-(4-Chlorophenylmethyl)-amino methyl]-oil of mirbane
4-[N-methyl-N-(4-bromophenyl methyl)-amino methyl]-oil of mirbane
4-[N-methyl-N-(3-Chlorophenylmethyl)-amino methyl]-oil of mirbane
4-[N-methyl-N-(3,4-dimethoxy benzene ylmethyl)-amino methyl]-oil of mirbane
4-[N-methyl-N-(4-anisole ylmethyl)-amino methyl]-oil of mirbane
4-[N-(2,2, the 2-trifluoroethyl)-N-phenmethyl-amino methyl]-oil of mirbane
4-[N-(2,2, the 2-trifluoroethyl)-N-(4-Chlorophenylmethyl)-amino methyl]-oil of mirbane
4-(2,6-dimethyl-piperidyl-methyl)-oil of mirbane
4-(thio-morpholinyl-methyl)-oil of mirbane
4-(S-oxygen base-thio-morpholinyl-methyl)-oil of mirbane
4-(S, S-dioxy base-thio-morpholinyl-methyl)-oil of mirbane
4-(azelidinyl-methyl)-oil of mirbane
4-(2,5-pyrrolin-1-base-methyl)-oil of mirbane
4-(3,6-dihydro-2H-pyridine-1-base-methyl)-oil of mirbane
4-(2-methoxycarbonyl-pyrrolidyl-methyl)-oil of mirbane
4-(3,5-dimethyl-piperidyl-methyl)-oil of mirbane
4-(4-phenyl-Piperazine base-methyl)-oil of mirbane
4-(4-phenyl-4-hydroxy-piperdine base-methyl)-oil of mirbane
4-[N-(3,4,5-trimethoxy-phenmethyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(3,4-dimethoxy-phenmethyl)-N-ethyl-amino methyl]-oil of mirbane
4-[N-(3-chlorophenylmethyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(2,6-dichlorobenzene methyl)]-N-methyl-amino methyl]-oil of mirbane
4-[N-(4-trifluoromethyl phenmethyl)-N-methyl-amino methyl]-oil of mirbane
4-(N-phenmethyl-N-sec.-propyl-amino methyl)-oil of mirbane
4-(the N-phenmethyl-N-tertiary butyl-amino methyl)-oil of mirbane
4-(diisopropylaminoethyl-methyl)-oil of mirbane
4-(di amino-methyl)-oil of mirbane
4-(diisobutyl amino-methyl)-oil of mirbane
4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-oil of mirbane
4-(2,3-dihydro-isoindole-2-base-methyl)-oil of mirbane
4-(6,7-dimethoxy-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-[N-(2-hydroxyethyl)-N-phenmethyl-amino methyl]-oil of mirbane
4-[N-(1-ethyl-amyl group)-N-(pyridine-2-base-methyl)-amino methyl]-oil of mirbane
4-(N-styroyl-N-methyl-amino methyl)-oil of mirbane
4-[N-(3,4-dihydroxyl-styroyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(3,4,5-trimethoxy-styroyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(3,4-dimethoxy-styroyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(4-nitro-styroyl)-N-methyl-amino methyl]-oil of mirbane
4-(N-styroyl-N-phenmethyl-amino methyl)-oil of mirbane
4-(N-styroyl-N-cyclohexyl-amino methyl)-oil of mirbane
4-[N-(2-(pyridine-2-yl)-ethyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(2-(pyridin-4-yl)-ethyl)-N-methyl-amino methyl]-oil of mirbane
4-[N-(pyridin-4-yl-methyl)-N-methyl-amino methyl]-oil of mirbane
4-[diphenyl-methyl amino-methyl]-oil of mirbane
4-[N-(4-nitro-phenmethyl)-N-propyl group-amino methyl]-oil of mirbane
4-[N-phenmethyl-N-(3-cyano group-propyl group)-amino methyl]-oil of mirbane
4-(N-phenmethyl-N-allyl group-amino methyl)-oil of mirbane
4-[N-(benzo (1,3) dioxole-5-base-methyl)-N-methyl-amino methyl]-oil of mirbane
4-(7-chloro-2,3,4,5-tetrahydrochysene-benzo (3) azatropylidene-3-base-methyl)-oil of mirbane
4-(7,8-two chloro-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-oil of mirbane
4-(7-methoxyl group-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-oil of mirbane
4-(7-methyl-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-oil of mirbane
4-(7,8-dimethoxy-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-oil of mirbane
4-(6,7-two chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(6,7-dimethyl-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(6-chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(7-chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(6-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(7-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-oil of mirbane
4-(2,3,4,5-tetrahydrochysene-azatropylidene (4,5-b) pyrazine-3-base-methyl)-oil of mirbane
4-(7-amino-2,3,4,5-tetrahydrochysene-azatropylidene (4,5-b) pyrazine-3-base-methyl)-oil of mirbane
4-(2-amino-5,6,7,8-tetrahydrochysene-azatropylidene (4,5-d) thiazole-6-base-methyl)-oil of mirbane
4-(5,6,7,8-tetrahydrochysene-azatropylidene (4,5-d) thiazole-6-base-methyl)-oil of mirbane
Embodiment VI 4-(N-ethyl-N-tert-butoxycarbonyl-amino methyl)-oil of mirbane
2.2 gram 4-(N-ethyl-amino methyl)-oil of mirbane is dissolved in 50 milliliters of vinyl acetic monomers, stirs 30 minutes under chambers temp with 2.6 gram tert-Butyl dicarbonates.Solution is with washing, and evaporation concentration then.
Output: 3.4 grams (theoretical value 97%),
R fValue: 0.90 (silica gel, methylene chloride=9: 1)
Prepare following compounds similar in appearance to the embodiment VI
4-[N-(4-Chlorophenylmethyl)-N-tert-butoxycarbonyl-amino methyl]-oil of mirbane
4-[N-cyclohexyl-N-tert-butoxycarbonyl-amino methyl]-oil of mirbane
4-[N-sec.-propyl-N-tert-butoxycarbonyl-amino methyl]-oil of mirbane
4-[N-butyl-N-tert-butoxycarbonyl-amino methyl]-oil of mirbane
4-[N-methoxycarbonyl methyl-N-tert-butoxycarbonyl-amino methyl]-oil of mirbane
4-(N-phenmethyl-N-tert-butoxycarbonyl-amino methyl)-oil of mirbane
4-(N-ethyl-N-tert-butoxycarbonyl-amino methyl)-oil of mirbane
Embodiment VII 4-(N-ethyl-N-tert-butoxycarbonyl-amino methyl)-aniline
6.4 gram 4-(N-ethyl-N-tert-butoxycarbonyl-amino methyl)-oil of mirbane is dissolved in 60 ml methanol, with the hydrogenation under room temperature and 3 crust of 1.5 gram Raney nickels.Leach catalyzer then, evaporating solns.
Output: 4.78 grams
R fValue: 0.70 (silica gel, methylene chloride=50: 1)
Prepare following compounds similar in appearance to the example VII:
4-[N-(4-Chlorophenylmethyl)-N-tert-butoxycarbonyl-amino methyl]-aniline
4-(N-cyclohexyl-N-tert-butoxycarbonyl-amino methyl)-aniline
4-(N-sec.-propyl-N-tert-butoxycarbonyl-amino methyl)-aniline
4-(N-butyl-N-tert-butoxycarbonyl-amino methyl)-aniline
4-(N-methoxycarbonyl methyl-N-tert-butoxycarbonyl-amino methyl)-aniline
4-(N-phenmethyl-N-tert-butoxycarbonyl-amino methyl)-aniline
4-(pyrrolidyl-methyl)-aniline
4-(morpholinyl-methyl)-aniline
4-(piperidyl-methyl)-aniline
4-(hexamethyleneimino-methyl)-aniline
4-(4-hydroxy-piperdine base-methyl)-aniline
4-(4-methyl-piperidyl-methyl)-aniline
4-(4-ethyl-piperidyl-methyl)-aniline
4-(4-sec.-propyl-piperidyl-methyl)-aniline
4-(4-phenyl-piperidyl-methyl)-aniline
4-(4-phenmethyl-piperidyl-methyl)-aniline
4-(4-ethoxy carbonyl-piperidyl-methyl)-aniline
4-(dimethylamino-methyl)-aniline
4-(two n-propylamine base-methyl)-aniline
4-(4-tert-butoxycarbonyl-piperazinyl-methyl)-aniline
3-(dimethylamino-methyl)-aniline
4-(2-diethylamino-ethyl)-aniline
4-(2-morpholinyl-ethyl)-aniline
4-(2-pyrrolidyl-ethyl)-aniline
4-(2-piperidyl-ethyl)-aniline
4-(N-ethyl-N-phenmethyl-amino methyl)-aniline
4-(N-propyl group-N-phenmethyl-amino methyl)-aniline
4-[N-methyl-N-(4-Chlorophenylmethyl)-amino methyl]-aniline
4-[N-methyl-N-(4-bromophenyl methyl)-amino methyl]-aniline
4-[N-methyl-N-(3-Chlorophenylmethyl)-amino methyl]-aniline
4-[N-methyl-N-(3,4-dimethoxy benzene ylmethyl)-amino methyl]-aniline
4-[N-methyl-N-(4-anisole ylmethyl)-amino methyl]-aniline
4-[N-(2,2, the 2-trifluoroethyl)-N-phenmethyl-amino methyl]-aniline
4-[N-(2,2, the 2-trifluoroethyl)-N-(4-Chlorophenylmethyl)-amino methyl]-aniline
4-(2,6-dimethyl-piperidyl-methyl)-aniline
4-(thio-morpholinyl-methyl)-aniline
4-(S-oxygen base-thio-morpholinyl-methyl)-aniline
4-(S, S-dioxy base-thio-morpholinyl-methyl)-aniline
4-(azelidinyl-methyl)-aniline
4-(2,5-pyrrolin-1-base-methyl)-aniline
4-(3,6-dihydro-2H-pyridine-1-base-methyl)-aniline
4-(2-methoxycarbonyl-pyrrolidyl-methyl)-aniline
4-(3,5-dimethyl-piperidyl-methyl)-aniline
4-(4-phenyl-piperidyl-methyl)-aniline
4-(4-phenyl-4-hydroxy-piperdine base-methyl)-aniline
4-[N-(3,4,5-trimethoxy-phenmethyl)-N-methyl-amino methyl]-aniline
4-[N-(3,4-trimethoxy-phenmethyl)-N-ethyl-amino methyl]-aniline
4-(N-phenmethyl-N-ethyl-amino methyl)-aniline
4-[N-(3-chlorophenylmethyl)-N-methyl-amino methyl]-aniline
4-[N-(2,6-dichlorobenzene methyl)-N-methyl-amino methyl]-aniline
4-[N-(4-trifluoromethyl phenmethyl)-N-methyl-amino methyl]-aniline
4-[N-phenmethyl-N-sec.-propyl-amino methyl)-aniline
4-(the N-phenmethyl-N-tertiary butyl-amino methyl)-aniline
4-(diisopropylaminoethyl-methyl)-aniline
4-(di amino-methyl)-aniline
4-(diisobutyl amino-methyl)-aniline
4-(2,3,4,5-tetrahydrochysene-benzo (d)-azatropylidene-3-base-methyl)-aniline
4-(2,3-dihydro-isoindole-2-base-methyl)-aniline
4-(6,7-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(N-(2-hydroxyethyl)-N-phenmethyl-amino methyl)-aniline
4-(N-(1-ethyl-amyl group)-N-(pyridine-2-base-methyl)-amino methyl]-aniline
4-(N-styroyl-N-methyl-amino methyl)-aniline
4-[N-(3,4-dihydroxyl-styroyl)-N-methyl-amino methyl]-aniline
4-[N-(3,4,5-trimethoxy-styroyl)-N-methyl-amino methyl]-aniline
4-[N-(3,4-dimethoxy-styroyl)-N-methyl-amino methyl]-aniline
4-[N-(4-nitro-styroyl)-N-methyl-amino methyl]-aniline
4-(N-styroyl-N-phenmethyl-amino methyl)-aniline
4-(N-styroyl-N-cyclohexyl-amino methyl)-aniline
4-[N-(2-(pyridine-2-yl)-ethyl)-N-methyl-amino methyl]-aniline
4-[N-(2-(pyridin-4-yl)-ethyl)-N-methyl-amino methyl]-aniline
4-[N-(pyridin-4-yl-methyl)-N-methyl-amino methyl]-aniline
4-(diphenyl-methyl amino-methyl)-aniline
4-[N-(4-nitro-phenmethyl)-N-propyl group-amino methyl]-aniline
4-[N-phenmethyl-N-(3-cyano group-propyl group)-amino methyl]-aniline
4-(N-phenmethyl-N-allyl group-amino methyl)-aniline
4-(N-phenmethyl-N-(2,2, the 2-trifluoroethyl)-amino methyl]-aniline
4-[N-(benzo (1,3) dioxole-5-base-methyl)-N-methyl-amino methyl]-aniline
4-(7-chloro-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-aniline
4-(7,8-two chloro-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-aniline
4-(7-methoxyl group-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-aniline
4-(7-methyl-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-aniline
4-(7,8-dimethoxy-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-aniline
4-(6,7-two chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(6,7-dimethyl-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(6-chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(7-chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(6-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(7-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline
4-(2,3,4,5-tetrahydrochysene-azatropylidene (4,5-b) pyrazine-3-base-methyl)-aniline
4-(7-amino-2,3,4,5-tetrahydrochysene-azatropylidene (4,5 ,-b) pyrazine-3-base-methyl)-aniline
4-(2-amino-5,6,7,8-tetrahydrochysene-azatropylidene (4,5 ,-d) thiazole-6-base-methyl)-aniline
4-(5,6,7,8-tetrahydrochysene-azatropylidene (4,5 ,-d) thiazole-6-base-methyl)-aniline
The preparation of end product:
Embodiment 13-Z-(1-phenyl amino-1-butyl-methylene radical)-5-amido-2-dihydroindole ketone
The prepared resin of 600 gram example IV is suspended in 3 milliliters of dimethyl formamides, shakes 10 hours at 70 ℃ with 0.4 gram aniline.Mixture filters then, and resin is with methylene dichloride, and methyl alcohol and dimethyl formamide washing are several times.Added 3 ml methanol ammonia through 2 hours then, with the cracking ethanoyl.At last, after with dimethylformamide and washed with dichloromethane, added 4 milliliters of 10% trifluoracetic acids in methylene dichloride through 90 minutes, separation resin, solution evaporation concentrates.Resistates is dissolved in a small amount of 1N sodium hydroxide solution, and with a small amount of dichloromethane extraction.Organic phase concentrates with rotary evaporation with dried over sodium sulfate.
Output: 37 milligrams
R fValue: 0.6 (silica gel, methylene chloride=9: 1)
C 20H 21N 3O 2
Mass spectrum: m/z=335 (M +)
Prepare following compounds similar in appearance to example 1:
(1) 3-Z-(1-phenyl amino-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (1) prepared resin and aniline preparation
R fValue: 0.59 (silica gel, methylene chloride=9: 1)
C 16H 13N 3O 2
Mass spectrum: m/z=279 (M +)
(2) 3-Z-[1-(4-methyl-phenyl amino)-1-methyl-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-monomethylaniline
R fValue: 0.44 (silica gel, methylene chloride=9: 1)
C 18H 17N 3O 2
Mass spectrum: m/z=307 (M +)
(3) 3-Z-(1-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-chloroaniline
R fValue: 0.45 (silica gel, methylene chloride=9: 1)
C 17H 14ClN 3O 2
Mass spectrum: m/z=327/329 (M +)
(4) 3-Z-[1-(4-ethyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-ethylaniline
R fValue: 0.43 (silica gel, methylene chloride=9: 1)
C 19H 19N 3O 2
Mass spectrum: m/z=321 (M +)
(5) 3-Z-[1-(4-methoxyl group-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-anisidine
R fValue: 0.46 (silica gel, methylene chloride=9: 1)
C 18H 17N 3O 3
Mass spectrum: m/z=323 (M +)
(6) 3-Z-[1-(4-iodo-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-Iodoaniline
R fValue: 0.36 (silica gel, methylene chloride=9: 1)
C 17H 14N 3O 2
Mass spectrum: m/z=419 (M +)
(7) 3-Z-[1-(4-fluoro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-fluoroaniline
R fValue: 0.60 (silica gel, methylene chloride=9: 1)
C 17H 14FN 3O 2
Mass spectrum: m/z=311 (M +)
(8) 3-Z-[1-(4-bromo-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-bromaniline
R fValue: 0.53 (silica gel, methylene chloride=9: 1)
C 17H 14BrN 3O 2
Mass spectrum: m/z=371/373 (M +)
(9) 3-Z-(1-phenyl amino-1-methyl-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and aniline preparation
R fValue: 0.58 (silica gel, methylene chloride=9: 1)
C 17H 15N 3O 2
Mass spectrum: m/z=293 (M +)
(10) 3-Z-(1-amino-1-methyl-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and ammonia preparation
R fValue: 0.23 (silica gel, methylene chloride=9: 1)
C 11H 11N 3O 2
Mass spectrum: m/z=217 (M +)
(11) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(piperidino methyl)-aniline preparation
R fValue: 0.31 (silica gel, methylene chloride=9: 1)
C 23H 26N 4O 2
Mass spectrum: m/z=390 (M +)
(12) 3-Z-[1-(4-pyrrolidyl methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-pyrrolidyl methyl-aniline preparation
R fValue: 0.20 (silica gel, methylene chloride=4: 1)
C 22H 24N 4O 2
Mass spectrum: m/z=376 (M +)
(13) 3-Z-[1-(4-dipropyl amino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment II (2) prepared resin and 4-dipropyl amino methyl-aniline preparation
R fValue: 0.71 (silica gel, methylene chloride=4: 1)
C 24H 30N 4O 2
Mass spectrum: m/z=406 (M +)
(14) 3-Z-[1-[4-(2-piperidyl ethyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(2-piperidyl ethyl)-aniline preparation
R fValue: 0.38 (silica gel, methylene chloride=4: 1)
C 24H 28N 4O 2
Mass spectrum: m/z=404 (M +)
(15) 3-Z-[1-[4-2-diethylamino ethyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(2-diethylamino ethyl)-aniline preparation
R fValue: 0.33 (silica gel, methylene chloride=4: 1)
C 23H 28N 4O 2
Mass spectrum: m/z=393 (M +)
(16) 3-Z-[1-(4-hexa-methylene formamino-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-hexamethyleneimino methyl-aniline preparation
R fValue: 0.34 (silica gel, methylene chloride=4: 1)
C 24H 28N 4O 2
Mass spectrum: m/z=404 (M +)
(17) 3-Z-[1-[4-(N-methyl-N-methylsulfonyl-amino)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(N-methyl-N-methylsulfonyl-amino)-aniline preparation
R fValue: 0.36 (silica gel, methylene chloride=9: 1)
C 19H 20N 4O 4S
Mass spectrum: m/z=400 (M +)
(18) 3-Z-[1-[4-methylsulfonyl amino-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-methylsulfonyl amino-aniline preparation
R fValue: 0.31 (silica gel, methylene chloride=9: 1)
C 18H 18N 4O 4S
Mass spectrum: m/z=386 (M +)
(19) 3-Z-[1-(4-bromophenyl amino)-1-ethyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (3) prepared resin and the preparation of 4-bromaniline
R fValue: 0.52 (silica gel, methylene chloride=9: 1)
C 18H 16BrN 3O 2
Mass spectrum: m/z=385/387 (M +/ M+2 +)
(20) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-ethyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (3) prepared resin and 4-piperidino methyl-aniline preparation
R fValue: 0.42 (silica gel, methylene chloride=4: 1)
C 24H 28N 4O 2
Mass spectrum: m/z=404 (M +)
(21) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-propyl group-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (4) prepared resin and 4-piperidino methyl-aniline preparation
R fValue: 0.49 (silica gel, methylene chloride=4: 1)
C 25H 30N 4O 2
Mass spectrum: m/z=418 (M +)
(22) 3-Z-[1-(4-bromophenyl amino)-1-propyl group-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (4) prepared resin and the preparation of 4-bromaniline
R fValue: 0.53 (silica gel, methylene chloride=9: 1)
C 19H 18BrN 3O 2
Mass spectrum: m/z=399/401 (M +/ M+2 +)
(23) 3-Z-[(4-bromophenyl amino)-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (I) prepared resin and the preparation of 4-bromaniline
C 16H 12BrN 3O 2
Mass spectrum: m/z=357/359 (M +/ M+2 +)
(24) 3-Z-[(4-piperidino methyl-phenyl amino)-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (I) prepared resin and 4-piperidino methyl-aniline preparation
C 22H 24N 4O 2
Mass spectrum: m/z=376 (M +)
(25) 3-Z-[1-(4-bromophenyl amino)-1-butyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV prepared resin and the preparation of 4-bromaniline
R fValue: 0.53 (silica gel: methylene chloride=9: 1)
C 20H 20BrN 3O 2
Mass spectrum: m/z=413/415 (M +/ M+2 +)
(26) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-butyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV prepared resin and 4-piperidino methyl-aniline preparation
R fValue: 0.48 (silica gel: methylene chloride=4: 1)
C 26H 32N 4O 2
Mass spectrum: m/z=432 (M +)
(27) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-vinyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (5) prepared resin and 4-piperidino methyl-aniline preparation
(28) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-(3-bromopropyl)-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (6) prepared resin and 4-piperidino methyl-aniline preparation
(29) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-(2-phenyl sulfonyl ethyl)-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (7) prepared resin and 4-piperidino methyl-aniline preparation
(30) 3-Z-[1-[4-(lupetidine ylmethyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(lupetidine ylmethyl)-aniline preparation
(31) 3-Z-[1-(4-thiomorpholine ylmethyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-thiomorpholine ylmethyl-aniline preparation
R fValue: 0.53 (silica gel, methylene chloride=9: 1)
C 22H 24N 4O 2S
Mass spectrum: m/z=408 (M +)
(32) 3-Z-[1-[(4-thio-morpholinyl-S-oxygen base-methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(thio-morpholinyl-S-oxygen base-methyl)-aniline preparation
R fValue: 0.21 (silica gel, methylene chloride=9: 1)
C 22H 24N 4O 3S
Mass spectrum: m/z=425 (M +)
(33) 3-Z-[1-[(4-thio-morpholinyl-S, S-dioxy base-methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(thio-morpholinyl-S, S-dioxy base-methyl)-aniline preparation
(34) 3-Z-[1-(4-azetidin ylmethyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-azetidin ylmethyl-aniline preparation
(35) 3-Z-[1-[4-(2,5-pyrrolin-1-base-methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(2,5-pyrrolin-1-base-methyl)-aniline preparation
R fValue: 0.10 (silica gel: methylene chloride=9: 1)
C 22H 22N 4O 2
Mass spectrum: m/z=375 (M+H +)
(36) 3-Z-[1-[4-(3,6-dihydro-2H-pyridine-1-base-methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(3,6-dihydro-2H-pyridine-1-base-methyl)-aniline preparation
R fValue: 0.20 (silica gel: methylene chloride=9: 1)
C 23H 24N 4O 2
Mass spectrum: m/z=389 (M+H) +
(37) 3-Z-[1-[4-(2-ethoxy carbonyl-pyrrolidyl methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(2-ethoxy carbonyl-pyrrolidyl methyl)-aniline preparation
R fValue: 0.50 (silica gel: methylene chloride=9: 1)
C 24H 26N 4O 2
Mass spectrum: m/z=435 (M+H) +
(38) 3-Z-[1-[4-(3,5-dimethyl-piperidino methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(3,5-dimethyl-piperidino methyl)-aniline preparation
R fValue: 0.16 (silica gel: methylene chloride=9: 1)
C 25H 30N 4O 2
Mass spectrum: m/z=418 (M +)
(39) 3-Z-[1-[4-(4-phenyl-Piperazine ylmethyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-(4-phenyl-Piperazine ylmethyl)-aniline preparation
R fValue: 0.40 (silica gel: methylene chloride=9: 1)
C 28H 29N 5O 2
Mass spectrum: m/z=468 (M+H) +
(40) 3-Z-[1-[4-(4-phenyl-4-hydroxy-piperdine ylmethyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-(4-phenyl-4-hydroxy-piperdine ylmethyl)-aniline preparation
C 29H 30N 4O 3
Mass spectrum: m/z=483 (M+H) +
(41) 3-Z-[1-(3-methoxyl group-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 3-methoxyl group-aniline preparation
R fValue: 0.40 (silica gel: methylene chloride=9: 1)
C 18H 17N 3O 3
Mass spectrum: m/z=323 (M +)
(42) 3-Z-[1-(3-ethoxy carbonyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 3-amino-ethyl benzoate preparation
C 20H 19N 3O 4
Mass spectrum: m/z=365 (M +)
(43) 3-Z-[1-(4-dimethylamino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-dimethylamino methyl-aniline preparation
C 20H 22N 4O 2
Mass spectrum: m/z=351 (M+H +)
(44) 3-Z-[1-[4-(4-cyclohexyl-piperidino methyl)-phenyl amino]-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(4-cyclohexyl-piperidino methyl)-aniline preparation
(45) 3-Z-[1-(4-morpholinyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-morpholinyl-aniline preparation
C 21H 22N 4O 3
Mass spectrum: m/z=378 (M +)
(46) 3-Z-[1-(N-methyl-piperidyl-4-base-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-amino-N-methyl-piperidines preparation
C 17H 22N 4O 2
Mass spectrum: m/z=314 (M +)
(47) 3-Z-[1-(4-methylcyclohexyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of 4-methyl-cyclohexyl base amine
C 18H 23N 3O 2
Mass spectrum: m/z=313 (M +)
(48) 3-Z-(1-cyclopentyl amino-1-methyl-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and the preparation of cyclopentyl amine
R fValue: 0.70 (silica gel: methylene chloride=4: 1)
C 16H 19N 3O 2
Mass spectrum: m/z=285 (M +)
(49) 3-Z-(1-sec.-propyl amino-1-methyl-methylene radical)-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and isopropylamine preparation
C 14H 17N 3O 2
Mass spectrum: m/z=259 (M +)
(50) 3-Z-[1-(4-ethoxy carbonyl methylamino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(ethoxy carbonyl methyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation
C 21H 22N 4O 4
Mass spectrum: m/z=394 (M +)
(51) 3-Z-[1-(4-phenmethyl amino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-(N-phenmethyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation
R fValue: 0.24 (silica gel, methylene chloride=9: 1)
C 25H 24N 4O 2
Mass spectrum: m/z=412 (M +)
(52) 3-Z-[1-(4-butyl amino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-(N-butyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation
R fValue: 0.40 (silica gel, methylene chloride=4: 1)
C 22H 26N 4O 2
Mass spectrum: m/z=378 (M +)
(53) 3-Z-[1-(4-ethylamino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-(N-ethyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation
R fValue: 0.20 (silica gel, methylene chloride=4: 1)
C 20H 22N 14O 2
Mass spectrum: m/z=351 (M+H +)
(54) 3-Z-[1-(4-cyclohexyl amino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-(N-cyclohexyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation
C 24H 28N 4O 2
Mass spectrum: m/z=405 (M +)
(55) 3-Z-[1-(4-sec.-propyl amino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
By embodiment IV (2) prepared resin and 4-(N-sec.-propyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation
C 21H 24N 4O 2
Mass spectrum: m/z=365 (M +)
(56) 3-Z-[1-(4-trifluoromethoxy-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By embodiment IV (2) prepared resin and 4-trifluoromethoxy-aniline preparation
C 18H 14F 3N 3O 3
Mass spectrum: m/z=377 (M +)
(57) 3-Z-[1-(4-difluoro-methoxy-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-difluoro-methoxy-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.5 (silica gel, methylene chloride=9: 1)
C 18H 15F 3N 3O 3
Mass spectrum: m/z=359 (M+H +)
(58) 3-Z-[1-(4-bromo-3-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 4-bromo-3-chloro-aniline by embodiment IV (2) manufacturing
C 17H 13BrClN 3O 2
Mass spectrum: m/z=405/407/409 (M +/ M+2 +/ M+4 +)
(59) 3-Z-[1-(4-trifluoromethyl-3-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-trifluoromethyl-3-bromo-aniline preparation by embodiment IV (2) manufacturing
C 18H 13BrF 3N 3O 2
Mass spectrum: m/z=439/441 (M+/M +2 +)
(60) 3-Z-[1-(4-chloro-phenyl amino)-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 4-chloro-aniline by embodiment IV (2) manufacturing
C 16H 12ClN 3O 2
Mass spectrum: m/z=312/314 (M +)
(61) 3-Z-[1-(3-bromo-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 3-bromo-aniline by embodiment IV (2) manufacturing
C 17H 14BrN 3O 2
Mass spectrum: m/z=371/373 (M +)
(62) 3-Z-[1-(3-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 3-chloro-aniline by embodiment IV (2) manufacturing
C 17H 14ClN 3O 2
Mass spectrum: m/z=327/329 (M +)
(63) 3-Z-[1-(2-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 2-chloro-aniline by embodiment IV (2) manufacturing
C 17H 14ClN 3O 2
Mass spectrum: m/z=327/329 (M +)
(64) 3-Z-[1-(4-bromo-3-methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-bromo-3-methyl-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.60 (silica gel, methylene chloride=9: 1)
C 18H 16BrN 3O 2
Mass spectrum: m/z=385/387 (M +)
(65) 3-Z-[1-(4-bromo-3-methoxyl group-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-bromo-3-methoxyl group-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.60 (silica gel, methylene chloride=9: 1)
C 18H 16BrN 3O 2
Mass spectrum: m/z=401/403 (M +)
(66) 3-Z-[1-(4-fluoro-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-fluoro-3-nitro-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 17H 13FN 4O 4
Mass spectrum: m/z=356 (M +)
(67) 3-Z-[1-(4-bromo-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-bromo-3-nitro-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 17H 13BrN 4O 4
Mass spectrum: m/z=416/418 (M +)
(68) 3-Z-[1-(4-ethyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-ethyl-3-nitro-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.70 (silica gel, methylene chloride=9: 1)
C 19H 18N 4O 4
Mass spectrum: m/z=366 (M +)
(69) 3-Z-[1-(4-chloro-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-chloro-3-nitro-aniline preparation by embodiment IV (2) manufacturing
C 17H 13ClN 4O 4
Mass spectrum: m/z=371/373 (M +)
(70) 3-Z-[1-(3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 3-nitro-aniline preparation by embodiment IV (2) manufacturing
C 17H 14N 4O 4
Mass spectrum: m/z=338 (M+H +)
(71) 3-Z-[1-(4-methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-methyl-3-nitro-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 18H 16N 4O 4
Mass spectrum: m/z=352 (M +)
(72) 3-Z-[1-(4-bromo-3-methoxycarbonyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 2-bromo-5-amino-methyl benzoate preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 19H 16BrN 3O 4
Mass spectrum: m/z=429/431 (M+H +)
(73) 3-Z-[1-(4-formamyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 4-aminobenzamide by embodiment IV (2) manufacturing
R fValue: 0.20 (silica gel, methylene chloride=9: 1)
C 18H 16N 4O 3
Mass spectrum: m/z=336 (M +)
(74) 3-Z-[1-(4-(piperidyl-carbonyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 1-(4-amino-benzoyl)-piperidines preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 23H 24N 4O 3
Mass spectrum: m/z=404 (M +)
(75) 3-Z-[1-(4-(2-diethylamino)-ethyl-formamyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone trifluoroacetate
Resin and 4-amino-N-[2-(diethylamino)-ethyl by embodiment IV (2) manufacturing]-the benzamide preparation
R fValue: 0.30 (silica gel, methylene chloride=9: 1)
C 24H 39N 5O 3
Mass spectrum: m/z=436 (M+H +)
(76) 3-Z-[1-(4-trifluoromethyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-trifluoromethyl-aniline preparation by embodiment IV (2) manufacturing
C 18H 14F 3N 3O 2
Mass spectrum: m/z=361 (M +)
(77) 3-Z-[1-(3-hydroxymethyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 3-amino-benzene methyl alcohol by embodiment IV (2) manufacturing
C 18H 17N 3O 3
Mass spectrum: m/z=323 (M +)
(78) 3-Z-[1-(4-hydroxycarbonyl group-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and the preparation of 4-benzaminic acid by embodiment IV (2) manufacturing
R fValue: 0.20 (silica gel, methylene chloride=4: 1)
C 18H 15N 3O 4
Mass spectrum: m/z=336 (M-H +)
(79) 3-Z-[1-(4-oxyethyl group carbon back methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-amino-2-nitro-phenyl vinyl acetic monomer preparation by embodiment IV (2) manufacturing
R fValue: 0.70 (silica gel, methylene chloride=9: 1)
C 21H 20N 4O 6
Mass spectrum: m/z=424 (M +)
(80) 3-Z-[1-(3-methoxycarbonyl-4-methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 3-amino-6-methyl-benzoic ether preparation by embodiment IV (2) manufacturing
R fValue: 0.70 (silica gel, methylene chloride=9: 1)
C 20H 19N 3O 4
Mass spectrum: m/z=365 (M +)
(81) 3-Z-[1-(3-diethylamino formyl radical-4-methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 3-amino-6-methyl-phenylformic acid diethylamide preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 23H 26N 4O 3
Mass spectrum: m/z=406 (M +)
(82) 3-Z-[1-(3-ethylamino formyl radical-4-methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 3-amino-6-methyl-phenylformic acid ethanamide preparation by embodiment IV (2) manufacturing
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 21H 22N 4O 3
Mass spectrum: m/z=378 (M +)
(83) 3-Z-[1-(3-sulfamyl-4-methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 3-amino-6-methyl-phenylbenzimidazole sulfonic acid acid amides preparation by embodiment IV (2) manufacturing
R fValue: 0.30 (silica gel, methylene chloride=9: 1)
C 18H 18N 4O 4S
Mass spectrum: m/z=386 (M +)
(84) 3-Z-[1-(3-acetylamino-4-methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-amino-2-acetylamino-toluene preparation by embodiment IV (2) manufacturing
R fValue: 0.65 (silica gel, methylene chloride=9: 1)
C 20H 20N 4O 3
Mass spectrum: m/z=364 (M +)
(85) 3-Z-[1-(4-(2-dimethylamino-oxyethyl group)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(2-methylamino-oxyethyl group)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.10 (silica gel, methylene chloride=4: 1)
C 21H 24N 4O 3
Mass spectrum: m/z=380 (M +)
(86) 3-Z-[1-(4-(2-piperidyl-oxyethyl group)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(2-piperidyl-oxyethyl group)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.70 (silica gel, methylene chloride=4: 1)
C 24H 28N 4O 3
Mass spectrum: m/z=420 (M +)
(87) 3-Z-[1-(4-(3-dimethylamino-propoxy-)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(3-dimethylamino-propoxy-)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.10 (silica gel, methylene chloride=4: 1)
C 22H 26N 4O 3
Mass spectrum: m/z=394 (M +)
(88) 3-Z-[1-(4-(3-piperidyl-propoxy-)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(3-piperidyl-propoxy-)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.20 (silica gel, methylene chloride=4: 1)
C 25H 30N 4O 3
Mass spectrum: m/z=434 (M +)
(89) 3-Z-[1-(4-(3-(N-phenmethyl-N-methylamino)-propoxy-)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[3-(N-phenmethyl-N-methylamino)-propoxy-by embodiment IV (2) manufacturing]-the aniline preparation
R fValue: 0.60 (silica gel, methylene chloride=4: 1)
C 28H 30N 4O 3
Mass spectrum: m/z=470 (M +)
(90) 3-Z-[1-(4-(N-phenmethyl-amino methyl)-phenyl amino)-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation by embodiment IV (1) manufacturing
C 24H 22N 4O 3
Mass spectrum: m/z=399 (M+H +)
(91) 3-Z-[1-(4-(N-(4-chlorophenylmethyl)-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(4-chlorophenylmethyl-N-tert-butoxycarbonyl-amino methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 25H 23ClN 4O 2
Mass spectrum: m/z=446/448 (M +)
(92) 3-Z-[1-(4-(N-(3,4,5-trimethoxy phenmethyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(3,4,5-trimethoxy-phenmethyl)-N-methyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 29H 32N 4O 5
Mass spectrum: m/z=516 (M +)
(93) 3-Z-[1-(4-(N-(3,4-dimethoxy-phenmethyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(3,4-dimethoxy-phenmethyl)-N-methyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 28H 30N 4O 4
Mass spectrum: m/z=486 (M +)
(94) 3-Z-[1-(4-(N-(3,4-dimethoxy-phenmethyl)-N-ethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(3,4-dimethoxy-phenmethyl)-N-ethyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 29H 32N 4O 4
Mass spectrum: m/z=500 (M +)
(95) 3-Z-[1-(4-(N-phenmethyl-N-ethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-ethyl-amino methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 27H 28N 4O 2
Mass spectrum: m/z=440 (M +)
(96) 3-Z-[1-(4-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-methyl-amino methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.55 (silica gel, methylene chloride=9: 1)
C 26H 26N 4O 2
Mass spectrum: m/z=426 (M +)
(97) 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-ethyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-methyl-amino methyl)-aniline preparation by embodiment IV (3) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 27H 28N 4O 2
Mass spectrum: m/z=440 (M +)
(98) 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-propyl group-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-methyl-amino-methyl)-aniline preparation by embodiment IV (4) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 28H 30N 4O 2
Mass spectrum: m/z=454 (M +)
(99) 3-Z-[1-(4-(N-(4-chlorophenylmethyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(4-chlorophenylmethyl)-N-methyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 26H 25CIN 4O 2
Mass spectrum: m/z=460/462 (M +)
(100) 3-Z-[1-(4-(N-(3-chlorophenylmethyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(3-chlorophenylmethyl)-N-methyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 26H 25CIN 4O 2
Mass spectrum: m/z=460/462 (M +)
(101) 3-Z-[1-(4-(N-(2,6-dichlorobenzene methyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(2,6-dichlorobenzene methyl)-N-methyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.38 (silica gel, methylene chloride=9: 1)
C 26H 24Cl 2N 4O 2
Mass spectrum: m/z=494/496/498 (M+2 +/ M+4 +)
(102) 3-Z-[1-(4-(N-(4-trifluoromethyl phenmethyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(4-trifluoromethyl-phenmethyl)-N-methyl-amino methyl by embodiment IV (2) manufacturing)-the aniline preparation
R fValue: 0.38 (silica gel, methylene chloride=9: 1)
C 27H 25F 3N 4O 2
Mass spectrum: m/z=494 (M +)
(103) 3-Z-[1-(4-(N-phenmethyl-N-sec.-propyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-sec.-propyl-amino methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 28H 30N 4O 2
Mass spectrum: m/z=454 (M +)
(104) 3-Z-[1-(4-(the N-phenmethyl-N-tertiary butyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(the N-phenmethyl-N-tertiary butyl-amino methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 29H 32N 4O 2
Mass spectrum: m/z=468 (M +)
(105) 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-methyl-amino methyl)-aniline preparation by embodiment IV (1) manufacturing
C 25H 24N 4O 2
Mass spectrum: m/z=413 (M+H +)
(106) 3-Z-[1-(4-(N-phenmethyl-N-ethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-phenmethyl-N-ethyl-amino methyl)-aniline preparation by embodiment IV (1) manufacturing
C 26H 26N 4O 2
Mass spectrum: m/z=427 (M+H +)
(107) 3-Z-[1-(4-(diisopropylaminoethyl-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(diisopropylaminoethyl-methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=4: 1)
C 24H 30N 4O 2
Mass spectrum: m/z=406 (M +)
(108) 3-Z-[1-(4-(di amino-methyl)-phenyl amino)-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(di amino-methyl)-aniline preparation by embodiment IV (2) manufacturing
C 23H 28N 4O 2
Mass spectrum: m/z=393 (M+H +)
(109) 3-Z-[1-(4-(two isobutyl amino-methyls)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(diisobutyl amino-methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 26H 34N 4O 2
Mass spectrum: m/z=434 (M +)
(110) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.30 (silica gel, methylene chloride=9: 1)
C 28H 28N 4O 2
Mass spectrum: m/z=452 (M +)
(111) 3-Z-[1-(4-(1,3-dihydro-isoindole-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(1,3-dihydro-isoindole-2-base-methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.35 (silica gel, methylene chloride=9: 1)
C 26H 24N 4O 2
Mass spectrum: m/z=425 (M+H +)
(112) 3-Z-[1-(4-(6,7-dimethoxy-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(6,7-dimethoxy-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 29H 30N 4O 4
Mass spectrum: m/z=499 (M+H +)
(113) 3-Z-[1-(4-(1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-aniline preparation by embodiment IV (2) manufacturing
(114) 3-Z-[1-(4-(N-(ethoxy carbonyl methyl)-N-phenmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(ethoxy carbonyl methyl)-N-phenmethyl-amino methyl by embodiment IV (2) manufacturing]-the aniline preparation
R fValue: 0.60 (silica gel, methylene chloride=9: 1)
C 29H 30N 4O 4
Mass spectrum: m/z=498 (M +)
(115) 3-Z-[1-(4-(N-(2-hydroxyethyl) N-phenmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(2-dihydroxy ethyl)-N-phenmethyl-amino methyl by embodiment IV (2) manufacturing]-the aniline preparation
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 27H 28N 4O 3
Mass spectrum: m/z=456 (M +)
(116) 3-Z-[1-(4-(N-(1-ethyl-amyl group)-N-(pyridine-2-base-methyl)-amino methyl) phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-[N-(1-ethyl-amyl group)-N-(pyridine-2-base-methyl)-amino methyl by embodiment IV (2) manufacturing]-the aniline preparation
R fValue: 0.45 (silica gel, methylene chloride=9: 1)
C 31H 37N 5O 2
Mass spectrum: m/z=511 (M +)
(117) 3-Z-[1-(4-(piperidyl-methyl)-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Resin and 4-(piperidyl-methyl)-3-nitro-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.70 (silica gel, methylene chloride=9: 1)
C 23H 25N 5O 4
Mass spectrum: m/z=436 (M+H +)
(118) 3-Z-[1-(4-(N-styroyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Resin and 4-(N-styroyl-N-methyl-amino methyl)-aniline preparation by embodiment IV (2) manufacturing
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 27H 28N 4O 2
Mass spectrum: m/z=441 (M+H +)
(119) 3-Z-[1-(4-(N-styroyl-N-ethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(120) 3-Z-[1-(4-(N-(3,4-dihydroxyl-styroyl)-N-methyl-amino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(121) 3-Z-[1-(4-(N-(3,4,5-trimethoxy-styroyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(122) 3-Z-[1-(4-(N-(3,4-dimethoxy-styroyl)-N-methyl-amino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(123) 3-Z-[1-(4-(N-(4-nitro-styroyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(124) 3-Z-[1-(4-(N-styroyl-N-phenmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 33H 32N 4O 2
Mass spectrum: m/z=517 (M+H +)
R fValue: 0.43 (silica gel, methylene chloride=9: 1)
(125) 3-Z-[1-(4-(N-styroyl-N-cyclohexyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(126) 3-Z-[1-(4-(N-(4-nitro-styroyl)-N-sec.-propyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(127) 3-Z-[1-(4-(N-(2-(pyridine-2-yl)-ethyl)-N-methyl-amino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 26H 27N 5O 2
Mass spectrum: m/z=441 (M +)
R fValue: 0.51 (silica gel, methylene chloride=4: 1)
(128) 3-Z-[1-(4-(N-(2-(pyridin-4-yl)-ethyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(129) 3-Z-[1-(4-(N-(pyridine-2-base-methyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(130) 3-Z-[1-(4-(N-(pyridin-3-yl-methyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(131) 3-Z-[1-(4-(N-(pyridin-4-yl-methyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(132) 3-Z-[1-(4-(diphenyl-methyl amino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 32H 30N 4O 2
Mass spectrum: m/z=503 (M+H +)
R fValue: 0.47 (silica gel, methylene chloride=9: 1)
(133) 3-Z-[1-(4-(N-(4-nitro-phenmethyl)-N-propyl group-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(134) 3-Z-[1-(4-(N-phenmethyl-N-(3-cyano group-propyl group)-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(135) 3-Z-[1-(4-(N-phenmethyl-N-allyl group-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 28H 26N 4O 2
Mass spectrum: m/z=453 (M+H +)
R fValue: 0.53 (silica gel, methylene chloride=9: 1)
(136) 3-Z-[1-(4-(imidazoles-1-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 21H 20N 6O 2
Mass spectrum: m/z=389 (M+H +)
R fValue: 0.20 (silica gel, methylene chloride=4: 1)
(137) 3-Z-[1-(4-(imidazoles-2-base-amino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(138) 3-Z-[1-(4-(N-phenmethyl-N-(2,2, the 2-trifluoroethyl)-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(139) 3-Z-[1-(4-(N-(benzo (1,3) dioxole-5-base-methyl)-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 27H 26N 4O 4
Mass spectrum: m/z=470 (M+H +)
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
(140) 3-Z-[1-(4-(7-chloro-2,3,4,5-tetrahydro benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(141) 3-Z-[1-(4-(7,8-two chloro-2,3,4,5-tetrahydro benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(142) 3-Z-[1-(4-(7-bromo-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(143) 3-Z-[1-(4-(7-fluoro-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(144) 3-Z-[1-(4-(7-methoxyl group-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(145) 3-Z-[1-(4-(7-methyl-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(146) 3-Z-[1-(4-(7,8-dimethoxy-2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(147) 3-Z-[1-(4-(6,7-two chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(148) 3-Z-[1-(4-(6,7-dimethyl-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(149) 3-Z-[1-(4-(6,7-two fluoro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 27H 26N 4O 2
Mass spectrum: m/z=439 (M+H +)
R fValue: 0.43 (silica gel, methylene chloride=9: 1)
(150) 3-Z-[1-(4-(6-chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(151) 3-Z-[1-(4-(7-chloro-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(152) 3-Z-[1-(4-(6-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(153) 3-Z-[1-(4-(7-methoxyl group-1,2,3,4-tetrahydrochysene-isoquinoline 99.9-2-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(154) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-azatropylidene (4,5 ,-b) pyrazine-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(155) 3-Z-[1-(4-(7-amino-2,3,4,5-tetrahydrochysene-azatropylidene (4,5 ,-b) pyrazine-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(156) 3-Z-[1-(4-(2-amino-5,6,7,8-tetrahydrochysene-azatropylidene (4,5 ,-d) thiazole-6-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(157) 3-Z-[1-(4-(5,6,7,8-tetrahydrochysene-azatropylidene (4,5 ,-b) thiazole-6-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(158) 3-Z-[1-(pyridin-3-yl-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(159) 3-Z-[1-(thiazol-2-yl-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(160) 3-Z-[1-(benzimidazolyl-2 radicals-Ji-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(161) 3-Z-[1-(5-methyl-isoxazole-3-bases-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(162) 3-Z-[1-(imidazoles-2-base-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(163) 3-Z-[1-(5-methyl-pyridine-2-base-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(164) 3-Z-[1-(5-bromo-pyridine-2-base-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(165) 3-Z-[1-(2-chloro-pyridine-2-base-amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(166) 3-Z-[1-(4-(N-butyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 23H 28N 4O 2
Mass spectrum: m/z=392 (M +)
(167) 3-Z-[1-(4-(N-isobutyl--amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 22H 26N 4O 2
Mass spectrum: m/z=378 (M +)
(168) 3-Z-[1-(4-(N-cyclohexyl methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
C 25H 30N 4O 2
Mass spectrum: m/z=418
R fValue: O.26 (silica gel, methylene chloride=4: 1)
Embodiment 23-Z-[1-(4-diethylamino formyl radical-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
The prepared resin of 2 gram embodiment IV b is with the method similar in appearance to embodiment 1, with 2 gram 4-subcutins in dimethyl formamide 110 ℃ of reactions.The resin of humidity load is suspended in 15 milliliters of dioxs and 15 ml methanol and 12 milliliters of 1N sodium hydroxide solutions stirred 40 hours.Mixture neutralizes with dilute hydrochloric acid then, with methylene dichloride, and methyl alcohol, and dimethyl formamide is washed.300 milligrams of resins are suspended in 3 milliliters of dimethyl formamides then, with 0.2 milliliter of diethylamine, and 0.5 gram TBTU (Tetrafluoroboric acid O-benzotriazole-1-base-N, N, N ＇, N ＇-tetramethyl- ), and 0.8 milliliter of N-ethyl-diisopropylamine at room temperature left standstill 40 hours.At last, product is by the resin cracking, as described in example 1 above.
Output: 61 milligrams
R fValue: 0.30 (silica gel, methylene chloride=9: 1)
C 22H 24N 4O 3
Mass spectrum: m/z=392 (M +)
Prepare following compounds similar in appearance to embodiment 2:
(1) 3-Z-[1-(4-phenmethyl formamyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with phenmethyl amine similar in appearance to embodiment 2
R fValue: 0.30 (silica gel, methylene chloride=9: 1)
C 25H 22N 4O 3
Mass spectrum: m/z=426 (M +)
(2) 3-Z-[1-(4-(N-methoxycarbonyl methyl-formamyl)-phenyl amino)-1-phenyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with glycine ethyl ester similar in appearance to embodiment 2
R fValue: 0.50 (silica gel, methylene chloride=9: 1)
C 21H 20N 4O 5
Mass spectrum: m/z=408 (M +)
(3) 3-Z-[1-(4-formyl-dimethylamino-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with dimethyl amine similar in appearance to embodiment 2
R fValue: 0.40 (silica gel, methylene chloride=9: 1)
C 20H 20N 4O 3
Mass spectrum: m/z=364 (M +)
(4) 3-Z-[1-(4-(N-(2-piperidyl-ethyl) formamyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Prepare with 1-(2-amino-ethyl)-piperidines similar in appearance to embodiment 2
R fValue: 0.30 (silica gel, methylene chloride=4: 1)
C 25H 29N 5O 3
Mass spectrum: m/z=448 (M+H +)
(5) 3-Z-[1-(4-(N-methyl-piperazinyl-formamyl)-phenyl amino)-1-phenyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
Prepare with N-methyl-piperazine similar in appearance to embodiment 2
R fValue: 0.40 (silica gel, methylene chloride=4: 1)
C 23H 25N 5O 3
Mass spectrum: m/z=419 (M +)
(6) 3-Z-[1-(4-(N-(2-diethylamino-ethyl)-N-methyl-formamyl-phenyl amino)-1-phenyl-methylene radical]-5-amido-2-dihydroindole ketone-trifluoroacetate
With N, N-diethyl-N ＇-methyl-second diamino prepares similar in appearance to embodiment 2
R fValue: 0.20 (silica gel, methylene chloride=4: 1)
C 25H 31N 5O 3
Mass spectrum: m/z=449 (M +)
(7) 3-Z-[1-(4 butyl formamyl-phenyl amino)-1-phenyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with butylamine similar in appearance to embodiment 2
R fValue: 0.80 (silica gel, methylene chloride=4: 1)
C 22H 24N 4O 3
Mass spectrum: m/z=392 (M +)
Embodiment 33-Z-[1-(4-(N-methyl-N-benzoyl-amino) phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
4.5 gram press the prepared resin of embodiment IV b to restrain 4-(9H-fluorenes-9-base-methoxycarbonyl)-methylaminos similar in appearance to the method for embodiment 1 and 3.4)-aniline reacts in dimethyl formamide.Then with 9H-fluorenes-9-base-methoxycarbonyl with 40 milliliter of 30% piperidines cracking in dimethyl formamide, resin wash is several times.Then 400 milligrams of resins are suspended in 4 milliliters of dimethyl formamides and the 0.3 milliliter of triethylamine, with 0.3 milliliter of benzoyl chlorine room temperature reaction 1 hour.At last, product with trifluoracetic acid by the resin cracking, as described in example 1 above.
Output: 25 milligrams
R fValue: 0.51 (silica gel, methylene chloride=9: 1)
C 30H 24N 4O 3
Mass spectrum: m/z=426 (M +)
Prepare following compounds similar in appearance to embodiment 3:
(1) 3-Z-[1-(4-(N-methyl-N-propionyl-amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with propionyl chlorine similar in appearance to embodiment 3
R fValue: 0.52 (silica gel, methylene chloride=9: 1)
C 21H 22N 4O 3
Mass spectrum: m/z=378 (M +)
(2) 3-Z-[1-(4-(N-methyl-N-butyryl radicals-amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with butyryl radicals chlorine similar in appearance to embodiment 3
R fValue: 0.28 (silica gel, methylene chloride=9: 1)
C 22H 24N 4O 3
Mass spectrum: m/z=392 (M +)
(3) 3-Z-[1-(4-(N-methyl-N-ethylsulfonyl-amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with ethylsulfonyl chlorine similar in appearance to embodiment 3
R fValue: 0.30 (silica gel, methylene chloride=9: 1)
C 20H 22N 4O 4S
Mass spectrum: m/z=413 (M-H +)
(4) 3-Z-[1-(4-(N-methyl-N-third alkylsulfonyl-amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with the third alkylsulfonyl chlorine similar in appearance to embodiment 3
R fValue: 0.31 (silica gel, methylene chloride=9: 1)
C 21H 24N 4O 4S
Mass spectrum: m/z=415 (M+Na +)
(5) 3-Z-[1-(4-(N-methyl-N-phenyl sulfonyl amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with phenyl sulfonyl chlorine similar in appearance to embodiment 3
R fValue: 0.46 (silica gel, methylene chloride=9: 1)
C 24H 22N 4O 4S
Mass spectrum: m/z=462 (M +)
(1) 3-Z-[1-(4-(N-methyl-N-ethanoyl-amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with ethanoyl chlorine similar in appearance to embodiment 3
R fValue: 0.20 (silica gel, methylene chloride=9: 1)
C 20H 20N 4O 3
Mass spectrum: m/z=364 (M +)
(7) 3-Z-[1-(4-(N-methyl-N-phenyl methyl alkylsulfonyl-amino)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
Prepare with the phenyl methanesulfonamide chloride of acid similar in appearance to embodiment 3
R fValue: 0.43 (silica gel, methylene chloride=9: 1)
C 25H 24N 4O 4S
Mass spectrum: m/z=475 (M-H +)
Embodiment 43-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester
8.0 gram (28 mmole) 1-ethanoyl-3-(1-oxyethyl group-1-methyl-methylene radical)-2-dihydroindole ketone-5-carboxylate methyl ester is dissolved in 60 milliliters of dimethyl formamides, stirs 6 hours at 80 ℃ with 6.3 gram (28 mmole) 4-(N-phenmethyl-N-methyl-amino methyl)-aniline.Add 30 milliliters of dense ammonia then, mixture was placed 2 hours at 45 ℃.Solution evaporation, resistates is washed with ethanol and ether.Then on little silicagel column with vinyl acetic monomer/ethanol (9: 1) chromatography.
Output: 8.6 grams (theoretical value 70%)
Fusing point: 150-152 ℃
C 27H 27N 3O 3
Mass spectrum: m/z=442 (M-H +)
Prepare following compounds similar in appearance to embodiment 4:
(1) 3-Z-[1-(4-(piperidyl-methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester
C 24H 27N 3O 3
Mass spectrum: m/z=406 (M+H +)
(2) 3-Z-[1-(4-bromo-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester
C 18H 15BrN 2O 3
Mass spectrum: m/z=386/388 (M +)
(3) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester
C 18H 15ClN 2O 3
Mass spectrum: m/z=342/344 (M +)
(4) 3-Z-[1-(4-(N-methyl-N-methyl sulphonyl-amino)-phenyl amino)-1-ethyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester
C 20H 21N 3O 5S
Mass spectrum: m/z=415 (M +)
(5) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester
C 29H 29N 3O 2
Mass spectrum: m/z=467 (M +)
Embodiment 53-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid
2.3 gram (5 mmole) 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylate methyl ester is dissolved in 50 ml methanol and the 50 milliliters of dioxs, stirred 1 hour at 70 ℃ with 25 milliliters of 1N sodium hydroxide solutions.Mixture neutralizes with 25 milliliters of 1N hydrochloric acid then, is evaporated to dried.Resistates is to wash several times drying.
Output: 1.9 grams (theoretical value 85%)
C 26H 25N 3O 3
Mass spectrum: m/z=428 (M+H +)
Prepare following compounds similar in appearance to embodiment 5:
(1) 3-Z-[1-(4-(piperidyl-methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid
C 23H 25N 3O 3
Mass spectrum: m/z=392 (M+H +)
(2) 3-Z-[1-(4-bromo-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid
(3) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid
C 17H 13ClN 2O 3
Mass spectrum: m/z=327/329 (M-H +)
(4) 3-Z-[1-(4-(N-methyl-N-methyl sulphonyl-amino)-phenyl amino)-1-ethyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid
C 19H 19N 3O 5S
Mass spectrum: m/z=401 (M +)
(5) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid
C 28H 27N 3O 3
Mass spectrum: m/z=453 (M +)
Embodiment 63-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-diethylamino formyl radical-2-dihydroindole ketone
0.3 gram 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-carboxylic acid and 1.2 restrains N-ethyl-diisopropyl ethyl amines and is dissolved in 8 milliliters of dimethyl formamides.Add 0.1 gram diethylamine and 0.4 gram TBTU (Tetrafluoroboric acid O-benzotriazole-1-base-N, N, N ＇, N ＇-tetramethyl-then
Figure A9980688400661
), mixture left standstill 20 hours in room temperature.Evaporation then, resistates suspends in water, with dichloromethane extraction.Organic phase evaporation, on silicagel column with methylene dichloride/ethanol (19: 1) chromatography.
Output: 0.2 gram (theoretical value 68%)
R fValue: 0.36 (silica gel, methylene chloride=19: 1)
C 30H 34N 4O 2
Mass spectrum: m/z=482 (M +)
Prepare following compounds similar in appearance to embodiment 6:
(1) 3-Z-[1-(4-(piperidyl-methyl)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-diethylamino formyl radical-2-dihydroindole ketone
Compound and diethylamine preparation by manufacturing among the embodiment 5 (1)
C 27H 34N 4O 2
Mass spectrum: m/z=446 (M +)
(2) 3-Z-[1-(4-(N-methyl-N-methyl sulphonyl-amino)-phenyl amino)-1-methyl-methylene radical]-2-dihydroindole ketone-5-diethylamino formyl radical-2-dihydroindole ketone
Compound and diethylamine preparation by manufacturing among the embodiment 5 (4)
C 23H 28N 4O 4S
Mass spectrum: m/z=457 (M+H +)
(3) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-diethylamino formyl radical-2-dihydroindole ketone
(4) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-formyl-dimethylamino-2-dihydroindole ketone
(5) 3-Z-[1-(4-(N-phenyl methyl-N-methylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-methylamino formyl radical-2-dihydroindole ketone
(6) 3-Z-[1-(4-(N-phenyl methyl-N-methylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-formyl-dimethylamino-2-dihydroindole ketone
(7) 3-Z-[1-(4-(N-phenyl methyl-N-methylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-diethylamino formyl radical-2-dihydroindole ketone
(8) 3-Z-[1-(4-(N-phenyl methyl-N-methylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-propyl group formamyl-2-dihydroindole ketone
(9) 3-Z-[1-(4-(N-phenyl methyl-N-methylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-dipropyl formamyl-2-dihydroindole ketone
(10) 3-Z-[1-(4-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-methylamino formyl radical-2-dihydroindole ketone
(11) 3-Z-[1-(4-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-formyl-dimethylamino-2-dihydroindole ketone
(12) 3-Z-[1-(4-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-diethylamino formyl radical-2-dihydroindole ketone
(13) 3-Z-[1-(4-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-propyl group formamyl-2-dihydroindole ketone
(14) 3-Z-[1-(4-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-dipropyl formamyl-2-dihydroindole ketone
(15) 3-Z-[1-(3-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-methylamino formyl radical-2-dihydroindole ketone
(16) 3-Z-[1-(3-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-formyl-dimethylamino-2-dihydroindole ketone
(17) 3-Z-[1-(3-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-diethylamino formyl radical-2-dihydroindole ketone
(18) 3-Z-[1-(3-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-propyl group formamyl-2-dihydroindole ketone
(19) 3-Z-[1-(3-(dimethylamino-methyl)-phenyl amino)-1-methyl-methylene radical]-5-dipropyl formamyl-2-dihydroindole ketone
(20) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-methylamino formyl radical-2-dihydroindole ketone
(21) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-formyl-dimethylamino-2-dihydroindole ketone
(22) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-diethylamino formyl radical-2-dihydroindole ketone
(23) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-propyl group formamyl-2-dihydroindole ketone
(24) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-dipropyl formamyl-2-dihydroindole ketone
(25) 3-Z-[1-phenyl amino-1-methyl-methylene radical]-5-methylamino formyl radical-2-dihydroindole ketone
(26) 3-Z-[1-phenyl amino-1-methyl-methylene radical]-5-formyl-dimethylamino-2-dihydroindole ketone
(27) 3-Z-[1-phenyl amino-1-methyl-methylene radical]-5-diethylamino formyl radical-2-dihydroindole ketone
Embodiment 73-Z-[1-(4-methyl-3-amino-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
130 milligrams of 3-Z-[1-(4-methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone is dissolved in 9 ml methanol, with the hydrogenation under 3 crust hydrogen pressures at room temperature of 50 milligrams of Raney nickels.Leach catalyzer, evaporating solns.
Output: 97 milligrams (theoretical value 70%)
R fValue: 0.60 (silica gel, methylene dichloride/ethanol=4: 1)
C 18H 18N 4O 2
Mass spectrum: m/z=322 (M +)
Prepare following compounds similar in appearance to embodiment 7:
(1) 3-Z[1-(4-(piperidyl-methyl)-3-amino-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
By 3-Z[1-(4-(piperidyl-methyl)-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone preparation
R fValue: 0.15 (silica gel, methylene dichloride/ethanol=4: 1)
C 23H 27N 5O 2
Mass spectrum: m/z=406 (M+H +)
Embodiment 8 per 10 milliliters of dried ampoules that contain 75 milligrams of active substances
Constituent:
75.0 milligrams of active substances
50.0 milligrams of mannitols
Water for injection reaches 10.0 milliliters
Preparation:
Active substance and mannitol are soluble in water.After filling, the solution lyophilize.For making used solution, product is dissolved in the water for injection.
Embodiment 9 per 2 milliliters of dried ampoules that contain 35 milligrams of active substances
Constituent:
35.0 milligrams of active substances
100.0 milligrams of mannitols
Water for injection reaches 2.0 milliliters
Preparation:
Active substance and mannitol are soluble in water.After filling, the solution lyophilize.
Can used solution for preparation, product is dissolved in the water for injection.
Embodiment 10 contains the tablet of 50 milligrams of active substances
Constituent:
(1) active substance is 50.0 milligrams
(2) lactose is 98.0 milligrams
(3) W-Gum is 50.0 milligrams
(4) Polyvinylpyrolidone (PVP) is 15.0 milligrams
(5) Magnesium Stearate is 2.0 milligrams
215.0 milligram
Preparation:
(1), (2) and (3) mix, with the aqueous solution granulating of (4).(5) add in the dry granules material.Mixture tablet forming thus, biplane has facet on two planes, have one to cut apart indentation on the plane.
The diameter of sheet: 9 millimeters embodiment 11 contain the tablet of 350 milligrams of active substances
Constituent:
(1) active substance is 350.0 milligrams
(2) lactose is 136.0 milligrams
(3) W-Gum is 80.0 milligrams
(4) Polyvinylpyrolidone (PVP) is 30.0 milligrams
(5) Magnesium Stearate is 4.0 milligrams
600.0 milligram
Preparation:
(1), (2) and (3) mix, with the aqueous solution granulating of (4).(5) add in the dry granules material.Mixture tablet forming thus, biplane has facet on two planes, have one to cut apart indentation on the plane.
The diameter of sheet: 12 millimeters
Embodiment 12 contains the capsule of 50 milligrams of active substances
Constituent:
(1) active substance is 50.0 milligrams
(2) dried corn starch is 58.0 milligrams
(3) the powder lactose is 50.0 milligrams
(5) Magnesium Stearate is 2.0 milligrams
160.0 milligram
Preparation:
(1) with (3) development.To develop in the mixture of thing adding (2) and (4) vigorous stirring.
This powdered mixture is packed into the capsule packing machine in No. 3 hard gelatin capsules.
Embodiment 13 contains the capsule of 350 milligrams of active substances
Constituent:
(1) active substance is 350.0 milligrams
(2) dried corn starch is 46.0 milligrams
(3) the powder lactose is 30.0 milligrams
(5) Magnesium Stearate is 4.0 milligrams
430.0 milligram
Preparation:
(1) with (3) development.To develop in the mixture of thing adding (2) and (4) vigorous stirring.
This powdered mixture is packed into the capsule packing machine in No. 0 hard gelatin capsule.
Embodiment 14 contains the suppository of 100 milligrams of active substances
1 suppository contains:
100.0 milligrams of active substances
600.0 milligrams of polyoxyethylene glycol (M.W.1500)
460.0 milligrams of polyoxyethylene glycol (M.W.6000)
840.0 milligrams of monostearate polyethylene sorbitans
2,0000.0 milligrams
Preparation:
Polyoxyethylene glycol and Stearinsaeure polyethylene sorbitan are fused together.The active substance that grinds is dispersed in the melts under 40 ℃.Melt is cooled to 38 ℃, pours in the suppository mold of little precooling.

Claims (13)

1. descend the dihydroindole ketone that is substituted, its isomer and the salt thereof of general formula,
Figure A9980688400021
Wherein
X is oxygen or sulphur atom,
R 1Be a hydrogen atom, C 1-4-alkoxy carbonyl, or C 2-4-alkyloyl,
R 2Be a carboxyl, or C 1-4-alkoxyl group-carbonyl, or optionally through one or two C 1-3The aminocarboxyl that-alkyl replaces, substituting group can be identical or different,
R 3Be a hydrogen atom, or C 1-6-alkyl, it can relate to R 3-C (R 4NR 52 positions, one fluorine of the carbon atom of)=base, chlorine or bromine atom, hydroxyl, C 1-3-alkoxyl group, C 1-3-alkyl sulphinyl, C 1-3-alkyl sulfinyl, C 1-3-alkyl sulphonyl, phenyl sulfinyl, phenyl sulfinyl, phenyl sulfonyl, amino, C 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, C 2-5-alkanoylamino, or N-(C 1-3-alkylamino)-C 2-5-alkanoylamino replaces,
R 4Be a hydrogen atom, C 1-6-alkyl, or alternative ground warp C 1-3The C that-alkyl replaces 5-7-cycloalkyl is wherein relating to R 3-C (R 4NR 5The methylene radical of 3 or 4 positions of the carbon atom of)=base can be through a selectivity through a C 1-3The imino-that-alkyl replaces replaces,
One phenyl or naphthyl, it can be through following replacement:
One fluorine, chlorine, the bromine or iodine atom,
One methoxyl group, alternative through 1 to 3 fluorine atom replacement,
One C 2-3-alkoxyl group can be at 2 or 3 positions, one C 1-3-alkylamino, two-(C 1-3-alkyl)-amino, or the replacement of 5 to 7 Yuans ring alkylideneiminos, alkyl can replace through a phenyl in addition in abovementioned alkyl amino and the dialkyl amido,
Trifluoromethyl, amino, C 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, C 2-5-alkanoylamino, N-(C 1-3-alkyl)-C 2-5-alkanoylamino, C 1-5-alkyl sulfonyl-amino, N-(C 1-3-alkyl)-C 1-5-alkyl sulfonyl-amino, phenyl sulfonyl amino, N-(C 1-3-alkyl)-and phenyl sulfonyl amino, amino-sulfonyl, C 1-3-alkyl amino sulfonyl, or two-(C 1-3-alkyl)-and amino-sulfonyl, alkyl can replace through a phenyl in addition in abovementioned alkyl amino and the dialkyl amido,
One carbonyl, it is through monohydroxy, C 1-3-alkoxyl group, amino, C 1-3-alkylamino, or N-(C 1-5-alkyl)-C 1-3-alkylamino replaces, and wherein, the alkyl in the above-mentioned base can be in addition through a carboxyl, C 1-3-alkoxy carbonyl, or phenyl replacement, or at 2 or 3 position two-(C 1-3-alkyl)-and amino, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of 5 to 7 Yuans ring alkylideneiminos,
One C 1-3-alkyl is through an amino, C 1-7-alkylamino, C 5-7-epoxy group(ing) amino, C 5-7-cycloalkyl-C 1-3-alkylamino, or phenyl-C 1-3-alkylamino replaces, can be in addition through a C on the nitrogen-atoms of amino 1-3-alkyl replaces, and wherein hydrogen atom can be substituted by fluorine atom wholly or in part, through C 5-7-cycloalkyl, C 2-4-thiazolinyl, or C 1-4-alkyl replaces,
C in above-mentioned each situation 1-4-alkyl substituent can be in addition through a cyano group, carboxyl, C 1-3-alkoxy carbonyl, pyridyl, imidazolyl, benzo [1,3] dioxolyl (dioxo1e), or phenyl one, two, or three replacements, wherein phenyl can be through fluorine, chlorine, or bromine atoms, methyl, methoxyl group, trifluoromethyl, cyano group, or nitro replacement, substituting group can be identical or different, or can replace through monohydroxy in 2,3 or 4 positions
One C 1-3-alkyl, it can be through monohydroxy, carboxyl, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of N-phenyl-Piperazine base, through one 5 to 7 Yuans ring alkenylene imino-s, or the replacement of 4 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two C 1-3Alkyl is through a C 5-7-cycloalkyl or phenyl are through a C 1-3-alkyl, C 5-7-cycloalkyl, phenyl, carboxyl, or C 1-4-alkoxyl group-carbonyl, and through the monohydroxy replacement, the methylene radical in abutting connection with nitrogen-atoms in the above-mentioned secondary ring alkylideneimino can substitute by a carbonyl,
One C 1-3-alkyl, it replaces through one 5 to 7 Yuans ring alkylideneiminos, wherein, can condense one in case of necessity by fluorine by two adjacent carbonss in above-mentioned 5 to 7 Yuans ring alkylideneiminos, chlorine or bromine atom or methyl or methoxy one or dibasic phenyl, (wherein substituting group can be identical or different), or selectivity is through a fluorine, chlorine, bromine, or iodine atom, or methyl, methoxyl group, or the amino De oxazolyl that replaces, imidazolyl, thiazolyl, pyridyl, pyrazinyl, or pyrimidyl
Above-mentioned can be through mono-substituted phenyl through a fluorine, chlorine, or bromine atoms, or methyl, methoxyl group, or nitro replaces,
Be 5 Yuans heteroaryls, it contains an imino-, a Sauerstoffatom or sulphur atom or an imino-, and a Sauerstoffatom or sulphur atom and one or two nitrogen-atoms, or
Be 6 Yuans heteroaryls, contain one, two, or three nitrogen-atoms, wherein, above-mentioned 5 and 6 Yuans heteroaryls can be in addition through a chlorine or bromine atom or a methyl substituted, or can condense a phenyl ring through the carbon atom of two adjacency on above-mentioned 5 or 6 Yuans heteroaryls, and
R 5Be a hydrogen atom or C 1-3-alkyl.
The carboxyl that exists, amino, or imino-can be through the base replacement of cleavable in vivo.
2. according to the dihydroindole ketone that is substituted of the formula I of claim 1, its isomer and salt thereof, wherein
X is a Sauerstoffatom,
R 1Be a hydrogen atom,
R 2One aminocarboxyl,
R 3Be a hydrogen atom, or C 1-4-alkyl, it can relate to R 3-C (R 4NR 52 positions, the one chlorine or bromine atom or phenyl alkylsulfonyl of the carbon atom of)=base replaces,
R 4Be a hydrogen atom, C 1-3-alkyl, the cyclopentyl that selectivity replaces through monomethyl, or cyclohexyl relate to R in cyclopentyl and cyclohexyl 3-C (R 4NR 5The methylene radical of 3 or 4 positions of the carbon atom of)=base can substitute through the imino-that monomethyl replaces through a selectivity,
Be a phenyl, it can be through following replacement:
One fluorine, chlorine, the bromine or iodine atom,
The methoxyl group that one selectivity replaces through 1 to 3 fluorine atom,
One C 2-3-alkoxyl group, it can be in 2 or 3 positions through methylamino, dimethylamino, or 5 to 7 Yuans cycloalkylidene imino-s replacements, methyl can replace through a phenyl in addition in the wherein above-mentioned amino,
Trifluoromethyl, amino, C 2-5-alkanoylamino, N-(C 1-3-alkyl)-C 2-5-alkanoylamino, C 1-5-alkyl sulfonyl-amino, N (C 1-3-alkyl)-C 1-5-alkyl sulfonyl-amino, phenyl sulfonyl amino, N-(C 1-3-alkyl)-phenyl sulfonyl amino, or amino-sulfonyl, wherein alkyl can replace through a phenyl in addition in abovementioned alkyl amino and the dialkyl amido,
One carbonyl, it is through monohydroxy, C 1-3-alkoxyl group, amino, C 1-3-alkylamino, or N-(C 1-5-alkyl)-C 1-3-alkylamino replaces, and wherein, the alkyl in the above-mentioned base also can be through a carboxyl, C 1-3-alkoxy carbonyl, or phenyl replacement, or 2 or 3 position two-(C 1-3-alkyl)-and amino, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of 5 to 7 Yuans ring alkylideneiminos,
One C 1-3-alkyl is through an amino, C 1-7-alkylamino, C 5-7-cycloalkyl amino, C 5-7-cycloalkyl-C 1-3-alkylamino, or phenyl-C 1-3-alkylamino replaces, and amino nitrogen-atoms can be in addition through a C 1-3-alkyl replaces, and wherein hydrogen atom can be substituted by fluorine atom wholly or in part, through C 5-7-cycloalkyl, C 2-4-thiazolinyl, or C 1-4-alkyl replaces,
C in above-mentioned each situation 1-4-alkyl substituent can be in addition through a cyano group, carboxyl, C 1-3-alkoxy carbonyl, pyridyl, imidazolyl, benzo [1,3] dioxolyl (dioxole), or the phenyl replacement, wherein phenyl can be through a fluorine, chlorine, or bromine atoms, or methyl, methoxyl group, cyano group, trifluoromethyl, or the replacement of nitro list, or through fluorine, chlorine, or bromine atoms, or methyl, or methoxyl group two or three replacements, substituting group can be identical or different, or can replace through monohydroxy in 2,3 or 4 positions
One C 1-3-alkyl, it can be through monohydroxy, carboxyl, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, piperazinyl, N-(C 1-3-alkyl)-piperazinyl, or the replacement of N-phenyl-Piperazine base, through one 5 to 7 Yuans ring alkenylene imino-s, or the replacement of 4 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two C 1-3-alkyl is through a cyclohexyl or phenyl, through a C 1-3-alkyl, cyclohexyl, phenyl, carboxyl, or C 1-4-alkoxyl group-carbonyl, and through the monohydroxy replacement, and the methylene radical in abutting connection with nitrogen-atoms can substitute by a carbonyl in the above-mentioned ring alkylideneimino,
One C 1-3-alkyl, it replaces through one 5 to 7 Yuans ring alkylideneiminos, wherein, can condense a selectivity through fluorine at the ring alkylideneimino of the above-mentioned 5-7 ring carbon atom by 2 adjacency, chlorine or bromine atom or methyl or methoxy one or two replace, and the wherein phenyl that substituting group can be identical or different, an or selectivity is by an amino pyrazinyl that replaces, or thiazolyl
Above-mentioned can be through mono-substituted phenyl through a fluorine, chlorine, or bromine atoms, or methyl, methoxyl group, or nitro replaces,
Be one optionally through a chlorine or bromine atom or methyl substituted pyridyl,
Be that a selectivity replaces De oxazolyl ， isoxazolyl through monomethyl, imidazolyl, or thiazolyl can condense through the carbon atom and the phenyl ring of two adjacency, and
R 5Be a hydrogen atom or C 1-3-alkyl.
3. according to the dihydroindole ketone that is substituted of the formula I of claim 1 or 2, its isomer and salt thereof, wherein
R 5In 5 positions.
4. according to the dihydroindole ketone that is substituted of the formula I of claim 1, its isomer and salt thereof, wherein
X is a Sauerstoffatom,
R 1Be a hydrogen atom,
R 2In 5 positions, be an aminocarboxyl,
R 3Be a hydrogen atom, or C 1-4-alkyl, it can replace through a chlorine or bromine atom or phenyl alkylsulfonyl endways,
R 4Be a hydrogen atom, C 1-3-alkyl, or the cyclopentyl that replaces through monomethyl of selectivity, or cyclohexyl relate to R in cyclohexyl 3-C (R 4NR 5The methylene radical alternative of 4 positions of the carbon atom of)=base substitutes through the imino-that monomethyl replaces,
Be a phenyl, through following replacement:
One fluorine, chlorine, the bromine or iodine atom,
Monomethyl or ethyl can be through C under each situation 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, N-phenyl-Piperazine base, 5 to 6 Yuans ring alkenylene imino-s, or the replacement of 5 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two methyl, through a cyclohexyl or phenyl, through monomethyl, cyclohexyl, or phenyl, and through the monohydroxy replacement, or
Monomethyl or ethyl, it can replace through the phenyl that one 5 to 7 Yuans ring alkylideneiminos replace, other one on above-mentioned ring alkylideneimino the carbon atom through two adjacency condensed a phenyl ring,
Monomethyl or ethyl, it is through an amino, methylamino, or ethylamino replaces, its each nitrogen-atoms at amino replaces through a phenmethyl or styroyl in addition, and the phenyl in the wherein above-mentioned base can be through a fluorine, chlorine, or bromine atoms, or through monomethyl, methoxyl group, cyano group, trifluoromethyl, or the replacement of nitro list, or through fluorine, chlorine, or bromine atoms, or through methyl, or methoxyl group two or three replacements, each substituting group can be identical or different
Above-mentioned can be through mono-substituted phenyl in addition through a fluorine, chlorine, or bromine atoms, or monomethyl, methoxyl group, or nitro replaces, and
R 5Be a hydrogen atom or C 1-4-alkyl.
5. according to the dihydroindole ketone that is substituted of the formula I of claim 1, its isomer and salt thereof, wherein
X is a Sauerstoffatom,
R 1Be a hydrogen atom,
R 2In 5 positions, be an aminocarboxyl,
R 3Be a hydrogen atom or C 1-4-alkyl,
R 4Be a phenyl, it can be through following replacement:
One fluorine, chlorine, the bromine or iodine atom,
Monomethyl or ethyl can be through C under each situation 1-3-alkylamino, two-(C 1-3-alkyl)-and amino, thio-morpholinyl, 1-oxygen base-thio-morpholinyl, 1,1-dioxy base-thio-morpholinyl, N-phenyl-Piperazine base, 5 to 6 Yuans ring alkenylene imino-s, or the replacement of 5 to 7 Yuans ring alkylideneiminos, wherein above-mentioned 5 to 7 Yuans ring alkylideneiminos can be through one or two methyl, through a cyclohexyl or phenyl, through monomethyl, cyclohexyl, or phenyl, and through the monohydroxy replacement, or
Monomethyl or ethyl, it can be through one 5 to the 7 Yuans phenyl replacements that the ring alkylideneimino replaces in 4 positions, and the carbon atom through two adjacency condenses a phenyl ring on above-mentioned inferior ring alkylene imine base in addition,
Monomethyl or ethyl, it is through an amino, methylamino, or the ethylamino replacement, its each nitrogen-atoms at amino can replace through a phenmethyl in addition, and wherein phenyl can be through a fluorine, chlorine, or bromine atoms, or through monomethyl, methoxyl group, cyano group, trifluoromethyl, or the replacement of nitro list, replace through methyl or methoxy two, or replace through methyl or methoxy three, each substituting group can be identical or different
Above-mentioned can be through monobasic phenyl through a fluorine, chlorine, or bromine atoms, or monomethyl, methoxyl group, or nitro replaces, and
R 5Be a hydrogen atom or C 1-4-alkyl.
6. according to the dihydroindole ketone that is substituted of the formula I of claim 1, its isomer and salt thereof are following:
(a) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(b) 3-Z-[1-(4-bromo-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(c) 3-Z-[1-(4-piperidino methyl-phenyl amino)-1-butyl-methylene radical]-5-amido-2-dihydroindole ketone,
(d) 3-Z-[1-(4-chloro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(e) 3-Z-(1-phenyl amino-methylene radical)-5-amido-2-dihydroindole ketone,
(f) 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(g) 3-Z-[1-(4-(N-(4-chlorophenylmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(h) 3-Z-[1-(4-(N-phenmethyl-N-ethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(i) 3-Z-[1-(4-(N-phenmethyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(j) 3-Z-[1-(4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-methylene radical]-5-amido-2-dihydroindole ketone,
(k) 3-Z-[1-(4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-base-methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone,
(l) 3-Z-[1-(4-piperidino methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone, and
(m) 3-Z-[1-(4-methyl-3-nitro-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone
(7.3-Z-[1-4-(N-phenmethyl-N-methyl-amino methyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone and salt thereof.
(8.3-Z-[1-4-(2,3,4,5-tetrahydrochysene-benzo (d) azatropylidene-3-ylmethyl)-phenyl amino)-1-methyl-methylene radical]-5-amido-2-dihydroindole ketone and salt.
9. according to the physiologically acceptable salt of the compound of claim 1 to 8.
10. pharmaceutical composition, it contains in the claim 1 to 8 each compound or according to the salt of claim 9 and optionally one or more inert carrier and/or thinner.
11. according in the claim 1 to 8 each compound or according to the purposes of the salt of claim 9, it is used to prepare and a kind ofly is suitable for treating excessive or the outgrowth pharmaceutical composition of abnormal cells.
12. a method for preparing the pharmaceutical composition of claim 10 is characterized in that, adds in one or more inert carrier and/or the thinner with method non-chemically according to each the compound or the salt of claim 9 in the claim 1 to 8.
13. a method for preparing the compound of claim 1 to 9,
It is characterized in that,
A. the amine of the compound of general formula II and logical formula III reaction
Figure A9980688400081
In the formula II
X and R 3Such as in the claim 1 to 8 definition,
R 2' have a R in the claim 1 to 8 2Meaning,
R 6Be the protecting group of the nitrogen-atoms of a hydrogen atom or a lactam group,
R wherein 2' or R 6Also can the key that is connected a solid phase that a selectivity forms through a spacer one of in the base, another R 2' or R 6Base as above-mentioned definition, and
Z 1The table halogen atom, hydroxyl, alkoxyl group, or aralkoxy,
Figure A9980688400091
In the formula III
R 4And R 5As definition in the claim 1 to 8,
If need, the used any protecting group of the nitrogen-atoms of cracking lactam group then, or with the compound of gained by the solid phase cracking, or
B. be R in the preparation formula I 2Be the compound of one of aminocarboxyl described in the claim 1 to 8:
The chemical combination of logical formula IV is carried out amidated with the amine of general formula (V) R in the formula IV 1And R 3To R 5Such as in the claim 1 to 6 definition, or its reactive derivatives,
H-(R 7NR 8) the middle R of (V) formula (V) 7And R 8Can be identical or different, be hydrogen atom or C 1-3-alkyl,
Then,, the generalformula that contains an alkoxy carbonyl of gained is converted into corresponding carboxylic compound by hydrolysis if need, or
The generalformula that contains amino or alkylamino of gained can be converted into corresponding alkylamino or dialkylamino compound by alkylation or reductive alkylation, or
The generalformula that contains amino or alkylamino of gained is converted into corresponding acyl compounds by acidylate, or
The generalformula that contains a carboxyl of gained is converted into corresponding ester or aminocarboxyl compound by esterification or amidated, or
The generalformula that contains a nitro of gained is converted into corresponding aminocompound by reduction, or
If need, any protecting group of protective reaction base during the scission reaction, or
With its stereoisomers of generalformula parsing becoming of gained, or
The generalformula of gained is converted into its salt with inorganic or organic acid or alkali, particularly is converted into its physiologically acceptable salt of using on the medicine.
CN99806884A 1998-06-04 1999-05-28 Substituted indolinones, production thereof and their use as medicaments Pending CN1303374A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19824922.5 1998-06-04
DE19824922A DE19824922A1 (en) 1998-06-04 1998-06-04 Novel substituted indolinones, their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
CN1303374A true CN1303374A (en) 2001-07-11

Family

ID=7869856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99806884A Pending CN1303374A (en) 1998-06-04 1999-05-28 Substituted indolinones, production thereof and their use as medicaments

Country Status (23)

Country Link
EP (1) EP1100779A1 (en)
JP (1) JP2002516906A (en)
KR (1) KR20010043973A (en)
CN (1) CN1303374A (en)
AU (1) AU764782B2 (en)
BG (1) BG104938A (en)
BR (1) BR9910898A (en)
CA (1) CA2328291A1 (en)
CO (1) CO5050294A1 (en)
DE (1) DE19824922A1 (en)
EA (1) EA003514B1 (en)
EE (1) EE200000723A (en)
HR (1) HRP20000831A2 (en)
HU (1) HUP0102210A3 (en)
ID (1) ID27035A (en)
IL (1) IL138702A0 (en)
NO (1) NO20006138L (en)
PL (1) PL344467A1 (en)
SK (1) SK18222000A3 (en)
TR (1) TR200003515T2 (en)
WO (1) WO1999062882A1 (en)
YU (1) YU73900A (en)
ZA (1) ZA200005435B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100338036C (en) * 1998-04-15 2007-09-19 贝林格尔英格海姆法玛两合公司 Substd. indolinones having inhibiting effect on kinases and cycline/CDK complexes
CN100455568C (en) * 1999-10-13 2009-01-28 贝林格尔英格海姆法玛两合公司 6-position substituted indoline, production and use thereof as medicament
CN101735071A (en) * 2009-12-04 2010-06-16 大连凯飞精细化工有限公司 Method for producing 4-N,N-dimethylamino methylaniline
CN103102352A (en) * 2011-11-15 2013-05-15 山东亨利医药科技有限责任公司 Tyrosine kinase inhibitor indolinone derivative
CN103130775A (en) * 2011-11-22 2013-06-05 山东亨利医药科技有限责任公司 Indolinone derivatives serving as tyrosine kinase inhibitors
CN103848814A (en) * 2012-12-06 2014-06-11 山东亨利医药科技有限责任公司 Substituted indole ketone derivative as tyrosine kinase inhibitor

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6964977B2 (en) 2000-09-01 2005-11-15 Smithkline Beecham Corporation Oxindole derivatives
JP2004517049A (en) * 2000-09-01 2004-06-10 グラクソ　グループ　リミテッド Substituted oxindole derivatives as tyrosine kinase inhibitors
DE10117204A1 (en) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
EP1401415B1 (en) 2001-06-29 2006-06-21 AB Science Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
EP1434991B1 (en) 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
ATE343415T1 (en) * 2001-06-29 2006-11-15 Ab Science THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
WO2003002106A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
JP2005508336A (en) 2001-09-27 2005-03-31 アラーガン、インコーポレイテッド 3- (Arylamino) methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
DE102004012070A1 (en) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
PE20060777A1 (en) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
CN101547892B (en) * 2006-12-05 2014-08-20 艾尼纳制药公司 Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
GB201208775D0 (en) * 2012-05-18 2012-07-04 Uni I Oslo Chemical compounds
WO2024050297A1 (en) * 2022-09-02 2024-03-07 Deciphera Pharmaceuticals, Llc Ulk inhibitors and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE838623A (en) * 1976-02-16 1976-06-16 3-HYDROXYMETHYLENE-2-INDOLINONE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
US4145422A (en) * 1977-09-06 1979-03-20 Abbott Laboratories Aminomethylene oxindoles
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP0929520B1 (en) * 1996-08-23 2005-11-02 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100338036C (en) * 1998-04-15 2007-09-19 贝林格尔英格海姆法玛两合公司 Substd. indolinones having inhibiting effect on kinases and cycline/CDK complexes
CN100455568C (en) * 1999-10-13 2009-01-28 贝林格尔英格海姆法玛两合公司 6-position substituted indoline, production and use thereof as medicament
CN101735071A (en) * 2009-12-04 2010-06-16 大连凯飞精细化工有限公司 Method for producing 4-N,N-dimethylamino methylaniline
CN103102352A (en) * 2011-11-15 2013-05-15 山东亨利医药科技有限责任公司 Tyrosine kinase inhibitor indolinone derivative
CN103102352B (en) * 2011-11-15 2015-08-12 山东亨利医药科技有限责任公司 Tyrosine kinase inhibitor indolinone derivative
CN103130775A (en) * 2011-11-22 2013-06-05 山东亨利医药科技有限责任公司 Indolinone derivatives serving as tyrosine kinase inhibitors
CN103130775B (en) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 As the dihydroindole ketone derivate of tyrosine kinase inhibitor
CN103848814A (en) * 2012-12-06 2014-06-11 山东亨利医药科技有限责任公司 Substituted indole ketone derivative as tyrosine kinase inhibitor
CN103848814B (en) * 2012-12-06 2016-08-17 山东亨利医药科技有限责任公司 The full ketone derivatives of substituted indole as tyrosine kinase inhibitor

Also Published As

Publication number Publication date
EA003514B1 (en) 2003-06-26
HUP0102210A2 (en) 2001-11-28
TR200003515T2 (en) 2001-06-21
CA2328291A1 (en) 1999-12-09
YU73900A (en) 2003-04-30
SK18222000A3 (en) 2001-08-06
HRP20000831A2 (en) 2001-12-31
BG104938A (en) 2001-06-29
DE19824922A1 (en) 1999-12-09
BR9910898A (en) 2001-02-13
KR20010043973A (en) 2001-05-25
JP2002516906A (en) 2002-06-11
EE200000723A (en) 2002-04-15
ID27035A (en) 2001-02-22
PL344467A1 (en) 2001-11-05
NO20006138L (en) 2001-02-01
WO1999062882A1 (en) 1999-12-09
NO20006138D0 (en) 2000-12-01
AU4370799A (en) 1999-12-20
HUP0102210A3 (en) 2002-12-28
EA200100001A1 (en) 2001-08-27
AU764782B2 (en) 2003-08-28
IL138702A0 (en) 2001-10-31
ZA200005435B (en) 2002-01-07
EP1100779A1 (en) 2001-05-23
CO5050294A1 (en) 2001-06-27

Similar Documents

Publication Publication Date Title
CN1303374A (en) Substituted indolinones, production thereof and their use as medicaments
CN100338036C (en) Substd. indolinones having inhibiting effect on kinases and cycline/CDK complexes
CN1257891C (en) Nitrogenous five-membered ring compounds
CN1150171C (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
CN1224623C (en) 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
CN1279023C (en) Indole-3-sulphur derivatives
CN1192773C (en) Cyclic amine CCR3 antagonisis
CN1198825C (en) 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i] purin-5-one derivatives
CN1642552A (en) 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
CN100343237C (en) Amide derivative and medicine
CN1184471A (en) Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds
CN1286810C (en) 2-acyl indol derivatives and their use as anti-tumour agents
CN1157619A (en) Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them
CN1422268A (en) 5-alkylpyrido [2,3-D] pyrimidines tyrosine kinase inhibitors
CN1079464A (en) Treatment comprises the preparation method of the valuable indolone of illness of cholinergic function reduction and the derivative of indole dione
CN1087904A (en) Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof
CN1087086A (en) Thiazolylvinylphenylderivatives derivatives
CN1319090A (en) Novel substuted indolimones, their preparation process and use as medicine
CN1890218A (en) Tubulin inhibitors
CN1282743A (en) New beta-carbiline compounds, their preparation method and medicine composition conterning same
CN1921848A (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
CN1183770A (en) Piperazine derivs, medicaments contg. same, their use and process for preparing same
CN1059908A (en) Pyrimidine derivatives and medicine thereof
CN1352644A (en) I-amino triazolo [4,3-alpha] quinazoline -5-ones and/or -5-thiones inhibiting phosphodiesterase IV
CN1250542C (en) 2-(1H-indol-3-yl)-2-oxo-acetamides with antitumor activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1035727

Country of ref document: HK